{"entity":"abbott-laboratories","name":"Abbott Laboratories","kind":null,"summary":"Abbott Laboratories' timeline holds 545 claims from 2006 to 2026: 535 money & deals, 10 other. 9 are undated. The latest took effect on September 30, 2026.","counts":{"total":545,"by_kind":{"people":0,"money":535,"products":0,"models":0,"other":10}},"events":[{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories website: https://abbott.com\", undated. Claim clm_E677AE124C79, https://asof.is/claim/clm_E677AE124C79, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q306764.","url":"https://asof.is/claim/clm_E677AE124C79","accessed":"2026-11-09"},"kind":"other","predicate":"website","value":"https://abbott.com","status":"unverified","assertable":false,"why_not":"low_confidence","id":"clm_E677AE124C79","evidence":{"by":"own-site","on":"2026-11-08","quote":"Abbott Laboratories.","url":"https://www.abbott.com/en-us/homepage"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories listed on: NYSE\", undated. Claim clm_349DE9490A94, https://asof.is/claim/clm_349DE9490A94, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_349DE9490A94","accessed":"2026-11-09"},"kind":"other","predicate":"listed_on","value":"NYSE","status":"valid","assertable":true,"id":"clm_349DE9490A94","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories headquarters: Abbott Park\", undated. Claim clm_47ECD384B983, https://asof.is/claim/clm_47ECD384B983, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_47ECD384B983","accessed":"2026-11-09"},"kind":"other","predicate":"headquarters","value":"Abbott Park","status":"valid","assertable":true,"id":"clm_47ECD384B983","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories state of incorporation: IL\", undated. Claim clm_5EB4D6DCC26A, https://asof.is/claim/clm_5EB4D6DCC26A, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_5EB4D6DCC26A","accessed":"2026-11-09"},"kind":"other","predicate":"state_of_incorporation","value":"IL","status":"valid","assertable":true,"id":"clm_5EB4D6DCC26A","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories registrant name: ABBOTT LABORATORIES\", undated. Claim clm_78E1BC94DC92, https://asof.is/claim/clm_78E1BC94DC92, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_78E1BC94DC92","accessed":"2026-11-09"},"kind":"other","predicate":"registrant_name","value":"ABBOTT LABORATORIES","status":"valid","assertable":true,"id":"clm_78E1BC94DC92","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories fiscal year end: 12-31\", undated. Claim clm_7EA8A2BEA2BF, https://asof.is/claim/clm_7EA8A2BEA2BF, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_7EA8A2BEA2BF","accessed":"2026-11-09"},"kind":"other","predicate":"fiscal_year_end","value":"12-31","status":"valid","assertable":true,"id":"clm_7EA8A2BEA2BF","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_AB7AA73DD6DF, https://asof.is/claim/clm_AB7AA73DD6DF, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_AB7AA73DD6DF","accessed":"2026-11-09"},"kind":"other","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","status":"valid","assertable":true,"id":"clm_AB7AA73DD6DF","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cik: 0000001800\", undated. Claim clm_DC766CB8ACA6, https://asof.is/claim/clm_DC766CB8ACA6, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_DC766CB8ACA6","accessed":"2026-11-09"},"kind":"other","predicate":"cik","value":"0000001800","status":"valid","assertable":true,"id":"clm_DC766CB8ACA6","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories ticker: ABT\", undated. Claim clm_E39037FF4684, https://asof.is/claim/clm_E39037FF4684, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_E39037FF4684","accessed":"2026-11-09"},"kind":"other","predicate":"ticker","value":"ABT","status":"valid","assertable":true,"id":"clm_E39037FF4684","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":"2006-12-31","until":"2007-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 14,054,186,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_43978D9CD2C9, https://asof.is/claim/clm_43978D9CD2C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_43978D9CD2C9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"14,054,186,000 United States dollar","status":"superseded","assertable":true,"id":"clm_43978D9CD2C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2009, filed 2010-02-19"}},{"date":"2006-12-31","until":"2007-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 521,192,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_EA473BD097AA, https://asof.is/claim/clm_EA473BD097AA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_EA473BD097AA","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"521,192,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EA473BD097AA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-19"}},{"date":"2007-12-31","until":"2008-06-30","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 2,456,384,000 United States dollar\", as of 2007-12-31 (until 2008-06-30). Claim clm_06133819F221, https://asof.is/claim/clm_06133819F221, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_06133819F221","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,456,384,000 United States dollar","status":"superseded","assertable":true,"id":"clm_06133819F221","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-19"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 39,713,924,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_08CB81E0BF16, https://asof.is/claim/clm_08CB81E0BF16, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_08CB81E0BF16","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"39,713,924,000 United States dollar","status":"superseded","assertable":true,"id":"clm_08CB81E0BF16","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-02-19"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 25,914,238,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_1AE9E329ED59, https://asof.is/claim/clm_1AE9E329ED59, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_1AE9E329ED59","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"25,914,238,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1AE9E329ED59","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2009, filed 2010-02-19"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 17,778,540,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_EC2D6AAD0FF7, https://asof.is/claim/clm_EC2D6AAD0FF7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_EC2D6AAD0FF7","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"17,778,540,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EC2D6AAD0FF7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-02-19"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 4,578,545,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_F857B97BF253, https://asof.is/claim/clm_F857B97BF253, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_F857B97BF253","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"4,578,545,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F857B97BF253","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-02-19"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,314,021,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_53BF00022ED3, https://asof.is/claim/clm_53BF00022ED3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_53BF00022ED3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,314,021,000 United States dollar","status":"superseded","assertable":true,"id":"clm_53BF00022ED3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,406,585,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_611637E5B583, https://asof.is/claim/clm_611637E5B583, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_611637E5B583","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,406,585,000 United States dollar","status":"superseded","assertable":true,"id":"clm_611637E5B583","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,796,586,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_9FCEFBC20CAB, https://asof.is/claim/clm_9FCEFBC20CAB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_9FCEFBC20CAB","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,796,586,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9FCEFBC20CAB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2008-09-30","until":"2009-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,497,660,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_79675DAFEFFB, https://asof.is/claim/clm_79675DAFEFFB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_79675DAFEFFB","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,497,660,000 United States dollar","status":"superseded","assertable":true,"id":"clm_79675DAFEFFB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2008-09-30","until":"2008-12-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 2,810,343,000 United States dollar\", as of 2008-09-30 (until 2008-12-31). Claim clm_AD5025D43C51, https://asof.is/claim/clm_AD5025D43C51, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_AD5025D43C51","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,810,343,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AD5025D43C51","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2008-09-30","until":"2009-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,396,517,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_EE3783948414, https://asof.is/claim/clm_EE3783948414, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_EE3783948414","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,396,517,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EE3783948414","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2008-12-31","until":"2009-06-30","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 17,479,551,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_34A4F9C5D46A, https://asof.is/claim/clm_34A4F9C5D46A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_34A4F9C5D46A","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"17,479,551,000 United States dollar","status":"superseded","assertable":true,"id":"clm_34A4F9C5D46A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-02-19"}},{"date":"2008-12-31","until":"2009-06-30","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 42,419,204,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_90CA3B235E37, https://asof.is/claim/clm_90CA3B235E37, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_90CA3B235E37","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"42,419,204,000 United States dollar","status":"superseded","assertable":true,"id":"clm_90CA3B235E37","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-02-19"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 5,693,839,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_9A47D1F92763, https://asof.is/claim/clm_9A47D1F92763, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_9A47D1F92763","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"5,693,839,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9A47D1F92763","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-02-19"}},{"date":"2008-12-31","until":"2009-03-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,112,022,000 United States dollar\", as of 2008-12-31 (until 2009-03-31). Claim clm_DE2BC508C752, https://asof.is/claim/clm_DE2BC508C752, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_DE2BC508C752","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,112,022,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DE2BC508C752","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-19"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 29,527,552,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_F17A9DA7A446, https://asof.is/claim/clm_F17A9DA7A446, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_F17A9DA7A446","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"29,527,552,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F17A9DA7A446","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2009, filed 2010-02-19"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 6,718,368,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_6D1B34C8DAA9, https://asof.is/claim/clm_6D1B34C8DAA9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_6D1B34C8DAA9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,718,368,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6D1B34C8DAA9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,060,759,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_BF0249D28592, https://asof.is/claim/clm_BF0249D28592, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_BF0249D28592","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,060,759,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF0249D28592","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,874,795,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_CD7C420909AE, https://asof.is/claim/clm_CD7C420909AE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_CD7C420909AE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,874,795,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CD7C420909AE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 19,879,112,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_31EB1925EF50, https://asof.is/claim/clm_31EB1925EF50, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_31EB1925EF50","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"19,879,112,000 United States dollar","status":"superseded","assertable":true,"id":"clm_31EB1925EF50","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,494,876,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_3BEDCDE314E8, https://asof.is/claim/clm_3BEDCDE314E8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_3BEDCDE314E8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,494,876,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3BEDCDE314E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,545,912,443 shares\", as of 2009-06-30 (until 2009-09-30). Claim clm_5CA03662740C, https://asof.is/claim/clm_5CA03662740C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_5CA03662740C","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,545,912,443 shares","status":"superseded","assertable":true,"id":"clm_5CA03662740C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,204,304,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_7367F0AB540E, https://asof.is/claim/clm_7367F0AB540E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_7367F0AB540E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,204,304,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7367F0AB540E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,671,420,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_998AAAD07809, https://asof.is/claim/clm_998AAAD07809, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_998AAAD07809","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,671,420,000 United States dollar","status":"superseded","assertable":true,"id":"clm_998AAAD07809","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 47,630,017,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_D6BE0F2C8B81, https://asof.is/claim/clm_D6BE0F2C8B81, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm.","url":"https://asof.is/claim/clm_D6BE0F2C8B81","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"47,630,017,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D6BE0F2C8B81","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2009, filed 2009-08-07"}},{"date":"2009-09-30","until":"2010-01-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,546,738,426 shares\", as of 2009-09-30 (until 2010-01-31). Claim clm_2777291C1D6A, https://asof.is/claim/clm_2777291C1D6A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_2777291C1D6A","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,546,738,426 shares","status":"superseded","assertable":true,"id":"clm_2777291C1D6A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,875,915,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_359398B95B4A, https://asof.is/claim/clm_359398B95B4A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_359398B95B4A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,875,915,000 United States dollar","status":"superseded","assertable":true,"id":"clm_359398B95B4A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 49,846,820,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_369D8CA1A11D, https://asof.is/claim/clm_369D8CA1A11D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_369D8CA1A11D","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"49,846,820,000 United States dollar","status":"superseded","assertable":true,"id":"clm_369D8CA1A11D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2010-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,639,753,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_939A0E0F91C1, https://asof.is/claim/clm_939A0E0F91C1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_939A0E0F91C1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,639,753,000 United States dollar","status":"superseded","assertable":true,"id":"clm_939A0E0F91C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 21,335,055,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_BBD426555711, https://asof.is/claim/clm_BBD426555711, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_BBD426555711","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"21,335,055,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BBD426555711","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2010-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,761,336,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_F40C461D1F9A, https://asof.is/claim/clm_F40C461D1F9A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm.","url":"https://asof.is/claim/clm_F40C461D1F9A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,761,336,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F40C461D1F9A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 6,235,741,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_44311C0CCB22, https://asof.is/claim/clm_44311C0CCB22, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_44311C0CCB22","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"6,235,741,000 United States dollar","status":"superseded","assertable":true,"id":"clm_44311C0CCB22","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-02-19"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 8,809,339,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_68D91286EA36, https://asof.is/claim/clm_68D91286EA36, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_68D91286EA36","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,809,339,000 United States dollar","status":"superseded","assertable":true,"id":"clm_68D91286EA36","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-19"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 22,855,627,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_B8C5187C21F8, https://asof.is/claim/clm_B8C5187C21F8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_B8C5187C21F8","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"22,855,627,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B8C5187C21F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-02-19"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 30,764,707,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_BF21BA903CA4, https://asof.is/claim/clm_BF21BA903CA4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_BF21BA903CA4","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"30,764,707,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF21BA903CA4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2009, filed 2010-02-19"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 52,416,623,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_D9EBDA9C23A0, https://asof.is/claim/clm_D9EBDA9C23A0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_D9EBDA9C23A0","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"52,416,623,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D9EBDA9C23A0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-02-19"}},{"date":"2010-01-31","until":"2010-03-31","published":"2010-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,552,643,385 shares\", as of 2010-01-31 (until 2010-03-31). Claim clm_55DE04E4C63E, https://asof.is/claim/clm_55DE04E4C63E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm.","url":"https://asof.is/claim/clm_55DE04E4C63E","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,552,643,385 shares","status":"superseded","assertable":true,"id":"clm_55DE04E4C63E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2009, filed 2010-02-19"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,543,565,059 shares\", as of 2010-03-31 (until 2010-06-30). Claim clm_4A1D932E0016, https://asof.is/claim/clm_4A1D932E0016, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_4A1D932E0016","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,543,565,059 shares","status":"superseded","assertable":true,"id":"clm_4A1D932E0016","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 20,860,099,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_85CABEE68CB1, https://asof.is/claim/clm_85CABEE68CB1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_85CABEE68CB1","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"20,860,099,000 United States dollar","status":"superseded","assertable":true,"id":"clm_85CABEE68CB1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,698,354,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_882692ECC7C2, https://asof.is/claim/clm_882692ECC7C2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_882692ECC7C2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,698,354,000 United States dollar","status":"superseded","assertable":true,"id":"clm_882692ECC7C2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 1,566,820,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_8831A07FE77A, https://asof.is/claim/clm_8831A07FE77A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_8831A07FE77A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"1,566,820,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8831A07FE77A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,470,483,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_A7FED0A7C490, https://asof.is/claim/clm_A7FED0A7C490, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_A7FED0A7C490","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,470,483,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A7FED0A7C490","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 53,358,622,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_E59D8BD6F57C, https://asof.is/claim/clm_E59D8BD6F57C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm.","url":"https://asof.is/claim/clm_E59D8BD6F57C","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"53,358,622,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E59D8BD6F57C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2010, filed 2010-05-04"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,605,966,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_0D38DCBAC1D9, https://asof.is/claim/clm_0D38DCBAC1D9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910042282/0001104659-10-042282-index.htm.","url":"https://asof.is/claim/clm_0D38DCBAC1D9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,605,966,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0D38DCBAC1D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2010, filed 2010-08-05"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 19,911,709,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_90D583BDBB9B, https://asof.is/claim/clm_90D583BDBB9B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910042282/0001104659-10-042282-index.htm.","url":"https://asof.is/claim/clm_90D583BDBB9B","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"19,911,709,000 United States dollar","status":"superseded","assertable":true,"id":"clm_90D583BDBB9B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2010, filed 2010-08-05"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,544,028,722 shares\", as of 2010-06-30 (until 2010-09-30). Claim clm_9A07F66DD2FF, https://asof.is/claim/clm_9A07F66DD2FF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910042282/0001104659-10-042282-index.htm.","url":"https://asof.is/claim/clm_9A07F66DD2FF","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,544,028,722 shares","status":"superseded","assertable":true,"id":"clm_9A07F66DD2FF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2010, filed 2010-08-05"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 8,826,014,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_BC7C9A4BD8E1, https://asof.is/claim/clm_BC7C9A4BD8E1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910042282/0001104659-10-042282-index.htm.","url":"https://asof.is/claim/clm_BC7C9A4BD8E1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,826,014,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC7C9A4BD8E1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2010, filed 2010-08-05"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,321,702,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_CBC630AE4E8D, https://asof.is/claim/clm_CBC630AE4E8D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910042282/0001104659-10-042282-index.htm.","url":"https://asof.is/claim/clm_CBC630AE4E8D","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,321,702,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CBC630AE4E8D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2010, filed 2010-08-05"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 53,381,402,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_CCF6757E8FC3, https://asof.is/claim/clm_CCF6757E8FC3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910042282/0001104659-10-042282-index.htm.","url":"https://asof.is/claim/clm_CCF6757E8FC3","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"53,381,402,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CCF6757E8FC3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2010, filed 2010-08-05"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 57,373,620,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_0A2F6FD9A825, https://asof.is/claim/clm_0A2F6FD9A825, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910056473/0001104659-10-056473-index.htm.","url":"https://asof.is/claim/clm_0A2F6FD9A825","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"57,373,620,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0A2F6FD9A825","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2010, filed 2010-11-05"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,818,145,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_3550C577271B, https://asof.is/claim/clm_3550C577271B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910056473/0001104659-10-056473-index.htm.","url":"https://asof.is/claim/clm_3550C577271B","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,818,145,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3550C577271B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-11-05"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,181,185,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_5422E43B6140, https://asof.is/claim/clm_5422E43B6140, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910056473/0001104659-10-056473-index.htm.","url":"https://asof.is/claim/clm_5422E43B6140","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,181,185,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5422E43B6140","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2010, filed 2010-11-05"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 8,674,505,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_A55F00358DA8, https://asof.is/claim/clm_A55F00358DA8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910056473/0001104659-10-056473-index.htm.","url":"https://asof.is/claim/clm_A55F00358DA8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,674,505,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A55F00358DA8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2010, filed 2010-11-05"}},{"date":"2010-09-30","until":"2011-01-31","published":"2010-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,545,815,965 shares\", as of 2010-09-30 (until 2011-01-31). Claim clm_E1CB9197DEA5, https://asof.is/claim/clm_E1CB9197DEA5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910056473/0001104659-10-056473-index.htm.","url":"https://asof.is/claim/clm_E1CB9197DEA5","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,545,815,965 shares","status":"superseded","assertable":true,"id":"clm_E1CB9197DEA5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2010, filed 2010-11-05"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 21,403,932,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_F1A1F85FFC33, https://asof.is/claim/clm_F1A1F85FFC33, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465910056473/0001104659-10-056473-index.htm.","url":"https://asof.is/claim/clm_F1A1F85FFC33","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"21,403,932,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F1A1F85FFC33","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2010, filed 2010-11-05"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 6,087,581,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_16CB3FB094C5, https://asof.is/claim/clm_16CB3FB094C5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746911001056/0001047469-11-001056-index.htm.","url":"https://asof.is/claim/clm_16CB3FB094C5","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"6,087,581,000 United States dollar","status":"superseded","assertable":true,"id":"clm_16CB3FB094C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-18"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 59,462,266,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_273981693F13, https://asof.is/claim/clm_273981693F13, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746911001056/0001047469-11-001056-index.htm.","url":"https://asof.is/claim/clm_273981693F13","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"59,462,266,000 United States dollar","status":"superseded","assertable":true,"id":"clm_273981693F13","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-18"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,648,371,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_9C0B558E781A, https://asof.is/claim/clm_9C0B558E781A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746911001056/0001047469-11-001056-index.htm.","url":"https://asof.is/claim/clm_9C0B558E781A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,648,371,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9C0B558E781A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-18"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 22,388,135,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_D23ECD8FDCAC, https://asof.is/claim/clm_D23ECD8FDCAC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746911001056/0001047469-11-001056-index.htm.","url":"https://asof.is/claim/clm_D23ECD8FDCAC","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"22,388,135,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D23ECD8FDCAC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2010, filed 2011-02-18"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 35,166,721,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_FBAB25A659DE, https://asof.is/claim/clm_FBAB25A659DE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746911001056/0001047469-11-001056-index.htm.","url":"https://asof.is/claim/clm_FBAB25A659DE","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"35,166,721,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FBAB25A659DE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2010, filed 2011-02-18"}},{"date":"2011-01-31","until":"2011-03-31","published":"2011-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,547,581,805 shares\", as of 2011-01-31 (until 2011-03-31). Claim clm_0410A6F2C43D, https://asof.is/claim/clm_0410A6F2C43D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746911001056/0001047469-11-001056-index.htm.","url":"https://asof.is/claim/clm_0410A6F2C43D","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,547,581,805 shares","status":"superseded","assertable":true,"id":"clm_0410A6F2C43D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2010, filed 2011-02-18"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,554,282,988 shares\", as of 2011-03-31 (until 2011-06-30). Claim clm_0C2AEF8174B5, https://asof.is/claim/clm_0C2AEF8174B5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911026773/0001104659-11-026773-index.htm.","url":"https://asof.is/claim/clm_0C2AEF8174B5","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,554,282,988 shares","status":"superseded","assertable":true,"id":"clm_0C2AEF8174B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2011, filed 2011-05-06"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 61,651,363,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_4050A1B04C96, https://asof.is/claim/clm_4050A1B04C96, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911026773/0001104659-11-026773-index.htm.","url":"https://asof.is/claim/clm_4050A1B04C96","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"61,651,363,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4050A1B04C96","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2011, filed 2011-05-06"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 24,629,650,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_5DCA28624EBB, https://asof.is/claim/clm_5DCA28624EBB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911026773/0001104659-11-026773-index.htm.","url":"https://asof.is/claim/clm_5DCA28624EBB","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"24,629,650,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5DCA28624EBB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2011, filed 2011-05-06"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 2,740,156,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_B1458938F400, https://asof.is/claim/clm_B1458938F400, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911026773/0001104659-11-026773-index.htm.","url":"https://asof.is/claim/clm_B1458938F400","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,740,156,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B1458938F400","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2011, filed 2011-05-06"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,301,149,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_D67FB10D44D3, https://asof.is/claim/clm_D67FB10D44D3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911026773/0001104659-11-026773-index.htm.","url":"https://asof.is/claim/clm_D67FB10D44D3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,301,149,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D67FB10D44D3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-06"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,040,850,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_E6DA945AC1D9, https://asof.is/claim/clm_E6DA945AC1D9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911026773/0001104659-11-026773-index.htm.","url":"https://asof.is/claim/clm_E6DA945AC1D9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,040,850,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E6DA945AC1D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2011, filed 2011-05-06"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,773,453,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_19A69695BB00, https://asof.is/claim/clm_19A69695BB00, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911043664/0001104659-11-043664-index.htm.","url":"https://asof.is/claim/clm_19A69695BB00","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,773,453,000 United States dollar","status":"superseded","assertable":true,"id":"clm_19A69695BB00","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-04"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,616,291,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_2BC0D1181F4B, https://asof.is/claim/clm_2BC0D1181F4B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911043664/0001104659-11-043664-index.htm.","url":"https://asof.is/claim/clm_2BC0D1181F4B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,616,291,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2BC0D1181F4B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2011, filed 2011-08-04"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,077,018,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_507982939D85, https://asof.is/claim/clm_507982939D85, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911043664/0001104659-11-043664-index.htm.","url":"https://asof.is/claim/clm_507982939D85","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,077,018,000 United States dollar","status":"superseded","assertable":true,"id":"clm_507982939D85","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2011, filed 2011-08-04"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 62,004,241,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_6D8509B0B286, https://asof.is/claim/clm_6D8509B0B286, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911043664/0001104659-11-043664-index.htm.","url":"https://asof.is/claim/clm_6D8509B0B286","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"62,004,241,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6D8509B0B286","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2011, filed 2011-08-04"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 26,378,853,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_6DF1F94B8785, https://asof.is/claim/clm_6DF1F94B8785, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911043664/0001104659-11-043664-index.htm.","url":"https://asof.is/claim/clm_6DF1F94B8785","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"26,378,853,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6DF1F94B8785","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2011, filed 2011-08-04"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,556,576,533 shares\", as of 2011-06-30 (until 2011-09-30). Claim clm_8274522F4DD8, https://asof.is/claim/clm_8274522F4DD8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911043664/0001104659-11-043664-index.htm.","url":"https://asof.is/claim/clm_8274522F4DD8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,556,576,533 shares","status":"superseded","assertable":true,"id":"clm_8274522F4DD8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2011, filed 2011-08-04"}},{"date":"2011-08-22","until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories x username: AbbottNews\", as of 2011-08-22. Claim clm_4CCD509B66A0, https://asof.is/claim/clm_4CCD509B66A0, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q306764.","url":"https://asof.is/claim/clm_4CCD509B66A0","accessed":"2026-11-09"},"kind":"other","predicate":"x_username","value":"AbbottNews","status":"unverified","assertable":false,"why_not":"unverified","id":"clm_4CCD509B66A0","evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/AbbottNews","url":"https://abbott.com"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 5,049,299,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_49FCEA1321DC, https://asof.is/claim/clm_49FCEA1321DC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911061064/0001104659-11-061064-index.htm.","url":"https://asof.is/claim/clm_49FCEA1321DC","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,049,299,000 United States dollar","status":"superseded","assertable":true,"id":"clm_49FCEA1321DC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,816,665,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_60A7CF8613BF, https://asof.is/claim/clm_60A7CF8613BF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911061064/0001104659-11-061064-index.htm.","url":"https://asof.is/claim/clm_60A7CF8613BF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,816,665,000 United States dollar","status":"superseded","assertable":true,"id":"clm_60A7CF8613BF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 594,878,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_83E5B8F4B133, https://asof.is/claim/clm_83E5B8F4B133, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911061064/0001104659-11-061064-index.htm.","url":"https://asof.is/claim/clm_83E5B8F4B133","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"594,878,000 United States dollar","status":"superseded","assertable":true,"id":"clm_83E5B8F4B133","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 24,603,800,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_B0304BE94341, https://asof.is/claim/clm_B0304BE94341, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911061064/0001104659-11-061064-index.htm.","url":"https://asof.is/claim/clm_B0304BE94341","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"24,603,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B0304BE94341","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2012-01-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,557,795,578 shares\", as of 2011-09-30 (until 2012-01-31). Claim clm_E7CEC88C5131, https://asof.is/claim/clm_E7CEC88C5131, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911061064/0001104659-11-061064-index.htm.","url":"https://asof.is/claim/clm_E7CEC88C5131","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,557,795,578 shares","status":"superseded","assertable":true,"id":"clm_E7CEC88C5131","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 59,628,176,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_E8CD9FA5F500, https://asof.is/claim/clm_E8CD9FA5F500, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465911061064/0001104659-11-061064-index.htm.","url":"https://asof.is/claim/clm_E8CD9FA5F500","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"59,628,176,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E8CD9FA5F500","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 24,439,833,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_09169A44136C, https://asof.is/claim/clm_09169A44136C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746912001216/0001047469-12-001216-index.htm.","url":"https://asof.is/claim/clm_09169A44136C","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"24,439,833,000 United States dollar","status":"superseded","assertable":true,"id":"clm_09169A44136C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 38,851,259,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_80F33B0D967B, https://asof.is/claim/clm_80F33B0D967B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746912001216/0001047469-12-001216-index.htm.","url":"https://asof.is/claim/clm_80F33B0D967B","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"38,851,259,000 United States dollar","status":"superseded","assertable":true,"id":"clm_80F33B0D967B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 60,276,893,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_E061E4681AB9, https://asof.is/claim/clm_E061E4681AB9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746912001216/0001047469-12-001216-index.htm.","url":"https://asof.is/claim/clm_E061E4681AB9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"60,276,893,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E061E4681AB9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 4,728,000,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_E3BAB111231C, https://asof.is/claim/clm_E3BAB111231C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_E3BAB111231C","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,728,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E3BAB111231C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-21"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 5,751,948,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_E857AF3C6172, https://asof.is/claim/clm_E857AF3C6172, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746912001216/0001047469-12-001216-index.htm.","url":"https://asof.is/claim/clm_E857AF3C6172","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"5,751,948,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E857AF3C6172","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2011, filed 2012-02-21"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,812,820,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_FC9A90EC2807, https://asof.is/claim/clm_FC9A90EC2807, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746912001216/0001047469-12-001216-index.htm.","url":"https://asof.is/claim/clm_FC9A90EC2807","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,812,820,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FC9A90EC2807","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2011, filed 2012-02-21"}},{"date":"2012-01-31","until":"2012-03-31","published":"2012-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,572,356,859 shares\", as of 2012-01-31 (until 2012-03-31). Claim clm_E1EBF63517AF, https://asof.is/claim/clm_E1EBF63517AF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746912001216/0001047469-12-001216-index.htm.","url":"https://asof.is/claim/clm_E1EBF63517AF","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,572,356,859 shares","status":"superseded","assertable":true,"id":"clm_E1EBF63517AF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2011, filed 2012-02-21"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,573,391,467 shares\", as of 2012-03-31 (until 2012-06-30). Claim clm_1DFA7D7F2069, https://asof.is/claim/clm_1DFA7D7F2069, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912034444/0001104659-12-034444-index.htm.","url":"https://asof.is/claim/clm_1DFA7D7F2069","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,573,391,467 shares","status":"superseded","assertable":true,"id":"clm_1DFA7D7F2069","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,575,722,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_21EACF91396A, https://asof.is/claim/clm_21EACF91396A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912034444/0001104659-12-034444-index.htm.","url":"https://asof.is/claim/clm_21EACF91396A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,575,722,000 United States dollar","status":"superseded","assertable":true,"id":"clm_21EACF91396A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 62,415,801,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_311FA36284F8, https://asof.is/claim/clm_311FA36284F8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912034444/0001104659-12-034444-index.htm.","url":"https://asof.is/claim/clm_311FA36284F8","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"62,415,801,000 United States dollar","status":"superseded","assertable":true,"id":"clm_311FA36284F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 25,453,691,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_6B7C46E76D25, https://asof.is/claim/clm_6B7C46E76D25, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912034444/0001104659-12-034444-index.htm.","url":"https://asof.is/claim/clm_6B7C46E76D25","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"25,453,691,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6B7C46E76D25","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,456,633,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_D9ABEC05FB6F, https://asof.is/claim/clm_D9ABEC05FB6F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912034444/0001104659-12-034444-index.htm.","url":"https://asof.is/claim/clm_D9ABEC05FB6F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,456,633,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D9ABEC05FB6F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,345,910,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_E1E87B6DD7DE, https://asof.is/claim/clm_E1E87B6DD7DE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912034444/0001104659-12-034444-index.htm.","url":"https://asof.is/claim/clm_E1E87B6DD7DE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,345,910,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E1E87B6DD7DE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2018-03-31","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 50,000,000 United States dollar\", as of 2012-03-31 (until 2018-03-31). Claim clm_F26A204C1C56, https://asof.is/claim/clm_F26A204C1C56, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912034444/0001104659-12-034444-index.htm.","url":"https://asof.is/claim/clm_F26A204C1C56","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"50,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F26A204C1C56","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 24,486,960,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_40993F6FAAEB, https://asof.is/claim/clm_40993F6FAAEB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912055154/0001104659-12-055154-index.htm.","url":"https://asof.is/claim/clm_40993F6FAAEB","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"24,486,960,000 United States dollar","status":"superseded","assertable":true,"id":"clm_40993F6FAAEB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2012, filed 2012-08-07"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,104,421,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_49FD4920B6B3, https://asof.is/claim/clm_49FD4920B6B3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912055154/0001104659-12-055154-index.htm.","url":"https://asof.is/claim/clm_49FD4920B6B3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,104,421,000 United States dollar","status":"superseded","assertable":true,"id":"clm_49FD4920B6B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2012, filed 2012-08-07"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,807,100,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_4F0F9A9FCDF2, https://asof.is/claim/clm_4F0F9A9FCDF2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912055154/0001104659-12-055154-index.htm.","url":"https://asof.is/claim/clm_4F0F9A9FCDF2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,807,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4F0F9A9FCDF2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2012, filed 2012-08-07"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,052,776,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_9250460C542F, https://asof.is/claim/clm_9250460C542F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912055154/0001104659-12-055154-index.htm.","url":"https://asof.is/claim/clm_9250460C542F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,052,776,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9250460C542F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2012, filed 2012-08-07"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,569,333,729 shares\", as of 2012-06-30 (until 2012-09-30). Claim clm_9CD0F79343E3, https://asof.is/claim/clm_9CD0F79343E3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912055154/0001104659-12-055154-index.htm.","url":"https://asof.is/claim/clm_9CD0F79343E3","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,569,333,729 shares","status":"superseded","assertable":true,"id":"clm_9CD0F79343E3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-08-07"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 61,859,790,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_D512D0F32419, https://asof.is/claim/clm_D512D0F32419, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912055154/0001104659-12-055154-index.htm.","url":"https://asof.is/claim/clm_D512D0F32419","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"61,859,790,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D512D0F32419","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2012, filed 2012-08-07"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,989,053,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_03034FC0B962, https://asof.is/claim/clm_03034FC0B962, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912075249/0001104659-12-075249-index.htm.","url":"https://asof.is/claim/clm_03034FC0B962","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,989,053,000 United States dollar","status":"superseded","assertable":true,"id":"clm_03034FC0B962","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2012, filed 2012-11-07"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 63,257,738,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_0F6ED49CB4F4, https://asof.is/claim/clm_0F6ED49CB4F4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912075249/0001104659-12-075249-index.htm.","url":"https://asof.is/claim/clm_0F6ED49CB4F4","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"63,257,738,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0F6ED49CB4F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2012, filed 2012-11-07"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,996,948,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_485B77DCC4E1, https://asof.is/claim/clm_485B77DCC4E1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912075249/0001104659-12-075249-index.htm.","url":"https://asof.is/claim/clm_485B77DCC4E1","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,996,948,000 United States dollar","status":"superseded","assertable":true,"id":"clm_485B77DCC4E1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2012, filed 2012-11-07"}},{"date":"2012-09-30","until":"2013-01-31","published":"2012-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,580,667,737 shares\", as of 2012-09-30 (until 2013-01-31). Claim clm_A5733B5B97F8, https://asof.is/claim/clm_A5733B5B97F8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912075249/0001104659-12-075249-index.htm.","url":"https://asof.is/claim/clm_A5733B5B97F8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,580,667,737 shares","status":"superseded","assertable":true,"id":"clm_A5733B5B97F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2012, filed 2012-11-07"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,773,241,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_B817BB7C1C39, https://asof.is/claim/clm_B817BB7C1C39, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912075249/0001104659-12-075249-index.htm.","url":"https://asof.is/claim/clm_B817BB7C1C39","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,773,241,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B817BB7C1C39","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2012, filed 2012-11-07"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 27,014,175,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_CAE9CB28DB1F, https://asof.is/claim/clm_CAE9CB28DB1F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465912075249/0001104659-12-075249-index.htm.","url":"https://asof.is/claim/clm_CAE9CB28DB1F","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"27,014,175,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CAE9CB28DB1F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2012, filed 2012-11-07"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 26,720,961,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_24230E6F3612, https://asof.is/claim/clm_24230E6F3612, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746913001180/0001047469-13-001180-index.htm.","url":"https://asof.is/claim/clm_24230E6F3612","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"26,720,961,000 United States dollar","status":"superseded","assertable":true,"id":"clm_24230E6F3612","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 39,873,910,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_B4C1932FF6FA, https://asof.is/claim/clm_B4C1932FF6FA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746913001180/0001047469-13-001180-index.htm.","url":"https://asof.is/claim/clm_B4C1932FF6FA","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"39,873,910,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B4C1932FF6FA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 67,234,944,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_B8A0C7E5A98B, https://asof.is/claim/clm_B8A0C7E5A98B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746913001180/0001047469-13-001180-index.htm.","url":"https://asof.is/claim/clm_B8A0C7E5A98B","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"67,234,944,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B8A0C7E5A98B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 8,084,515,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_DB14BAE02A47, https://asof.is/claim/clm_DB14BAE02A47, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746913001180/0001047469-13-001180-index.htm.","url":"https://asof.is/claim/clm_DB14BAE02A47","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"8,084,515,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB14BAE02A47","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2012, filed 2013-02-15"}},{"date":"2012-12-31","until":"2013-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 5,963,000,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_E0C8ECF41AD1, https://asof.is/claim/clm_E0C8ECF41AD1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_E0C8ECF41AD1","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"5,963,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E0C8ECF41AD1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-21"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 10,802,163,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_FEB167E490AD, https://asof.is/claim/clm_FEB167E490AD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746913001180/0001047469-13-001180-index.htm.","url":"https://asof.is/claim/clm_FEB167E490AD","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"10,802,163,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FEB167E490AD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2012, filed 2013-02-15"}},{"date":"2013-01-31","until":"2013-03-31","published":"2013-02-15","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,570,677,029 shares\", as of 2013-01-31 (until 2013-03-31). Claim clm_EC2D60D2CF76, https://asof.is/claim/clm_EC2D60D2CF76, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746913001180/0001047469-13-001180-index.htm.","url":"https://asof.is/claim/clm_EC2D60D2CF76","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,570,677,029 shares","status":"superseded","assertable":true,"id":"clm_EC2D60D2CF76","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2012, filed 2013-02-15"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 42,686,613,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_765D69CF45D0, https://asof.is/claim/clm_765D69CF45D0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913038811/0001104659-13-038811-index.htm.","url":"https://asof.is/claim/clm_765D69CF45D0","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"42,686,613,000 United States dollar","status":"superseded","assertable":true,"id":"clm_765D69CF45D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,377,895,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_83226985F7C5, https://asof.is/claim/clm_83226985F7C5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913038811/0001104659-13-038811-index.htm.","url":"https://asof.is/claim/clm_83226985F7C5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,377,895,000 United States dollar","status":"superseded","assertable":true,"id":"clm_83226985F7C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 544,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_99925964117F, https://asof.is/claim/clm_99925964117F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm.","url":"https://asof.is/claim/clm_99925964117F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"544,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99925964117F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-07"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,373,120,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_C0BA9C433C47, https://asof.is/claim/clm_C0BA9C433C47, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913038811/0001104659-13-038811-index.htm.","url":"https://asof.is/claim/clm_C0BA9C433C47","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,373,120,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C0BA9C433C47","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 614,788,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_C62521896403, https://asof.is/claim/clm_C62521896403, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913038811/0001104659-13-038811-index.htm.","url":"https://asof.is/claim/clm_C62521896403","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"614,788,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C62521896403","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 22,588,186,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_CEDF1D0510CD, https://asof.is/claim/clm_CEDF1D0510CD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913038811/0001104659-13-038811-index.htm.","url":"https://asof.is/claim/clm_CEDF1D0510CD","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"22,588,186,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CEDF1D0510CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,558,864,658 shares\", as of 2013-03-31 (until 2013-06-30). Claim clm_DB844C28FB13, https://asof.is/claim/clm_DB844C28FB13, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913038811/0001104659-13-038811-index.htm.","url":"https://asof.is/claim/clm_DB844C28FB13","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,558,864,658 shares","status":"superseded","assertable":true,"id":"clm_DB844C28FB13","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 42,903,346,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_01D207199632, https://asof.is/claim/clm_01D207199632, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913060300/0001104659-13-060300-index.htm.","url":"https://asof.is/claim/clm_01D207199632","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"42,903,346,000 United States dollar","status":"superseded","assertable":true,"id":"clm_01D207199632","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,554,125,355 shares\", as of 2013-06-30 (until 2013-09-30). Claim clm_31493028904E, https://asof.is/claim/clm_31493028904E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913060300/0001104659-13-060300-index.htm.","url":"https://asof.is/claim/clm_31493028904E","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,554,125,355 shares","status":"superseded","assertable":true,"id":"clm_31493028904E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 5,572,254,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_3B7BA4C79E00, https://asof.is/claim/clm_3B7BA4C79E00, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913060300/0001104659-13-060300-index.htm.","url":"https://asof.is/claim/clm_3B7BA4C79E00","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,572,254,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3B7BA4C79E00","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 476,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_56D74673B58B, https://asof.is/claim/clm_56D74673B58B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm.","url":"https://asof.is/claim/clm_56D74673B58B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"476,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_56D74673B58B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,446,025,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_A00248C0A983, https://asof.is/claim/clm_A00248C0A983, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913060300/0001104659-13-060300-index.htm.","url":"https://asof.is/claim/clm_A00248C0A983","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,446,025,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A00248C0A983","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 627,476,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_A62E02723D32, https://asof.is/claim/clm_A62E02723D32, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913060300/0001104659-13-060300-index.htm.","url":"https://asof.is/claim/clm_A62E02723D32","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"627,476,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A62E02723D32","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 22,336,064,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_FA0A4E638F4A, https://asof.is/claim/clm_FA0A4E638F4A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913060300/0001104659-13-060300-index.htm.","url":"https://asof.is/claim/clm_FA0A4E638F4A","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"22,336,064,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FA0A4E638F4A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-09-30","until":"2014-01-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,546,185,646 shares\", as of 2013-09-30 (until 2014-01-31). Claim clm_03EB3A67DDC7, https://asof.is/claim/clm_03EB3A67DDC7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913082270/0001104659-13-082270-index.htm.","url":"https://asof.is/claim/clm_03EB3A67DDC7","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,546,185,646 shares","status":"superseded","assertable":true,"id":"clm_03EB3A67DDC7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2013, filed 2013-11-07"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,369,138,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_05BD8CC8CEE0, https://asof.is/claim/clm_05BD8CC8CEE0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913082270/0001104659-13-082270-index.htm.","url":"https://asof.is/claim/clm_05BD8CC8CEE0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,369,138,000 United States dollar","status":"superseded","assertable":true,"id":"clm_05BD8CC8CEE0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2013, filed 2013-11-07"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 630,339,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_102398756A32, https://asof.is/claim/clm_102398756A32, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913082270/0001104659-13-082270-index.htm.","url":"https://asof.is/claim/clm_102398756A32","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"630,339,000 United States dollar","status":"superseded","assertable":true,"id":"clm_102398756A32","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2013, filed 2013-11-07"}},{"date":"2013-09-30","until":"2014-03-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 966,000,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_2BB6EFB82CB5, https://asof.is/claim/clm_2BB6EFB82CB5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm.","url":"https://asof.is/claim/clm_2BB6EFB82CB5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"966,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2BB6EFB82CB5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 44,132,477,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_498E70E89BD2, https://asof.is/claim/clm_498E70E89BD2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913082270/0001104659-13-082270-index.htm.","url":"https://asof.is/claim/clm_498E70E89BD2","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"44,132,477,000 United States dollar","status":"superseded","assertable":true,"id":"clm_498E70E89BD2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2013, filed 2013-11-07"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 23,696,237,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_CFE8748CEC34, https://asof.is/claim/clm_CFE8748CEC34, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913082270/0001104659-13-082270-index.htm.","url":"https://asof.is/claim/clm_CFE8748CEC34","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"23,696,237,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CFE8748CEC34","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2013, filed 2013-11-07"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 2,882,454,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_F56B3CD1FDAB, https://asof.is/claim/clm_F56B3CD1FDAB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465913082270/0001104659-13-082270-index.htm.","url":"https://asof.is/claim/clm_F56B3CD1FDAB","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,882,454,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F56B3CD1FDAB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-11-07"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,475,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_11779D774E56, https://asof.is/claim/clm_11779D774E56, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_11779D774E56","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,475,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11779D774E56","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 25,171,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_25A96CED8FE3, https://asof.is/claim/clm_25A96CED8FE3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_25A96CED8FE3","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"25,171,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_25A96CED8FE3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 2,629,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_476B36EDFB32, https://asof.is/claim/clm_476B36EDFB32, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_476B36EDFB32","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"2,629,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_476B36EDFB32","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 21,848,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_9516B11C6785, https://asof.is/claim/clm_9516B11C6785, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_9516B11C6785","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"21,848,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9516B11C6785","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 42,953,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_BE81EC5EFEDD, https://asof.is/claim/clm_BE81EC5EFEDD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_BE81EC5EFEDD","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"42,953,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BE81EC5EFEDD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 2,576,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_C538B005C944, https://asof.is/claim/clm_C538B005C944, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_C538B005C944","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"2,576,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C538B005C944","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-21"}},{"date":"2014-01-31","until":"2014-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,543,070,300 shares\", as of 2014-01-31 (until 2014-03-31). Claim clm_F3B60AD32165, https://asof.is/claim/clm_F3B60AD32165, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm.","url":"https://asof.is/claim/clm_F3B60AD32165","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,543,070,300 shares","status":"superseded","assertable":true,"id":"clm_F3B60AD32165","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2013, filed 2014-02-21"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 451,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_1937F4CF953B, https://asof.is/claim/clm_1937F4CF953B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm.","url":"https://asof.is/claim/clm_1937F4CF953B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"451,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1937F4CF953B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-07"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,501,938,538 shares\", as of 2014-03-31 (until 2014-06-30). Claim clm_398EA7EAB5B8, https://asof.is/claim/clm_398EA7EAB5B8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm.","url":"https://asof.is/claim/clm_398EA7EAB5B8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,501,938,538 shares","status":"superseded","assertable":true,"id":"clm_398EA7EAB5B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2014, filed 2014-05-07"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 41,662,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_5B183F58E77F, https://asof.is/claim/clm_5B183F58E77F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm.","url":"https://asof.is/claim/clm_5B183F58E77F","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"41,662,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B183F58E77F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2014, filed 2014-05-07"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 375,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_604CF864E41B, https://asof.is/claim/clm_604CF864E41B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm.","url":"https://asof.is/claim/clm_604CF864E41B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"375,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_604CF864E41B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-07"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,244,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_B233A6055639, https://asof.is/claim/clm_B233A6055639, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm.","url":"https://asof.is/claim/clm_B233A6055639","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,244,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B233A6055639","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2014, filed 2014-05-07"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 23,390,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_C84177F7FADC, https://asof.is/claim/clm_C84177F7FADC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm.","url":"https://asof.is/claim/clm_C84177F7FADC","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"23,390,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C84177F7FADC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2014, filed 2014-05-07"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 2,060,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_DBA8DBEBFC34, https://asof.is/claim/clm_DBA8DBEBFC34, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm.","url":"https://asof.is/claim/clm_DBA8DBEBFC34","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,060,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBA8DBEBFC34","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2014, filed 2014-05-07"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 41,475,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_285888A38ED0, https://asof.is/claim/clm_285888A38ED0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm.","url":"https://asof.is/claim/clm_285888A38ED0","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"41,475,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_285888A38ED0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 23,602,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_820EF0E3F09E, https://asof.is/claim/clm_820EF0E3F09E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm.","url":"https://asof.is/claim/clm_820EF0E3F09E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"23,602,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_820EF0E3F09E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,570,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_AA75EDDF3D74, https://asof.is/claim/clm_AA75EDDF3D74, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm.","url":"https://asof.is/claim/clm_AA75EDDF3D74","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,570,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AA75EDDF3D74","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 466,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_B5440F9585CE, https://asof.is/claim/clm_B5440F9585CE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm.","url":"https://asof.is/claim/clm_B5440F9585CE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"466,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B5440F9585CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,503,699,033 shares\", as of 2014-06-30 (until 2014-09-30). Claim clm_CDA367FBFDF8, https://asof.is/claim/clm_CDA367FBFDF8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm.","url":"https://asof.is/claim/clm_CDA367FBFDF8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,503,699,033 shares","status":"superseded","assertable":true,"id":"clm_CDA367FBFDF8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 761,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_D93B193C9846, https://asof.is/claim/clm_D93B193C9846, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm.","url":"https://asof.is/claim/clm_D93B193C9846","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"761,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D93B193C9846","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,551,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_FD8317313DF1, https://asof.is/claim/clm_FD8317313DF1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm.","url":"https://asof.is/claim/clm_FD8317313DF1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,551,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FD8317313DF1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-09-30","until":"2015-01-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,505,790,586 shares\", as of 2014-09-30 (until 2015-01-31). Claim clm_046691A1A0C0, https://asof.is/claim/clm_046691A1A0C0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm.","url":"https://asof.is/claim/clm_046691A1A0C0","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,505,790,586 shares","status":"superseded","assertable":true,"id":"clm_046691A1A0C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 731,000,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_1340152CB9B1, https://asof.is/claim/clm_1340152CB9B1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm.","url":"https://asof.is/claim/clm_1340152CB9B1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"731,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1340152CB9B1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,104,000,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_82A6A707FD7C, https://asof.is/claim/clm_82A6A707FD7C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm.","url":"https://asof.is/claim/clm_82A6A707FD7C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,104,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_82A6A707FD7C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 42,514,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_CF1CC29BF075, https://asof.is/claim/clm_CF1CC29BF075, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm.","url":"https://asof.is/claim/clm_CF1CC29BF075","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"42,514,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF1CC29BF075","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,613,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_D03CCE99B6F0, https://asof.is/claim/clm_D03CCE99B6F0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm.","url":"https://asof.is/claim/clm_D03CCE99B6F0","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,613,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D03CCE99B6F0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 538,000,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_D2D95C54C305, https://asof.is/claim/clm_D2D95C54C305, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm.","url":"https://asof.is/claim/clm_D2D95C54C305","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"538,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D2D95C54C305","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 22,888,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_FE809BBE39B1, https://asof.is/claim/clm_FE809BBE39B1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm.","url":"https://asof.is/claim/clm_FE809BBE39B1","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"22,888,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FE809BBE39B1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 20,247,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_0D3539091ADB, https://asof.is/claim/clm_0D3539091ADB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746915001377/0001047469-15-001377-index.htm.","url":"https://asof.is/claim/clm_0D3539091ADB","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"20,247,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0D3539091ADB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2014, filed 2015-02-27"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,063,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_29AA3D4C2CD2, https://asof.is/claim/clm_29AA3D4C2CD2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746915001377/0001047469-15-001377-index.htm.","url":"https://asof.is/claim/clm_29AA3D4C2CD2","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,063,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_29AA3D4C2CD2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2014, filed 2015-02-27"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 41,275,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_2B6AC140F47C, https://asof.is/claim/clm_2B6AC140F47C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746915001377/0001047469-15-001377-index.htm.","url":"https://asof.is/claim/clm_2B6AC140F47C","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"41,275,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B6AC140F47C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2014, filed 2015-02-27"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 2,599,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_4095A5CF68FD, https://asof.is/claim/clm_4095A5CF68FD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746915001377/0001047469-15-001377-index.htm.","url":"https://asof.is/claim/clm_4095A5CF68FD","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"2,599,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4095A5CF68FD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2014, filed 2015-02-27"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 2,284,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_B11F523F3F14, https://asof.is/claim/clm_B11F523F3F14, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746915001377/0001047469-15-001377-index.htm.","url":"https://asof.is/claim/clm_B11F523F3F14","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"2,284,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B11F523F3F14","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2014, filed 2015-02-27"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 21,526,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_D31BB3649B18, https://asof.is/claim/clm_D31BB3649B18, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746915001377/0001047469-15-001377-index.htm.","url":"https://asof.is/claim/clm_D31BB3649B18","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"21,526,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D31BB3649B18","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2014, filed 2015-02-27"}},{"date":"2015-01-31","until":"2015-03-31","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,508,977,828 shares\", as of 2015-01-31 (until 2015-03-31). Claim clm_01EFFCB41E1C, https://asof.is/claim/clm_01EFFCB41E1C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746915001377/0001047469-15-001377-index.htm.","url":"https://asof.is/claim/clm_01EFFCB41E1C","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,508,977,828 shares","status":"superseded","assertable":true,"id":"clm_01EFFCB41E1C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2014, filed 2015-02-27"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 2,292,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_1C02430C4950, https://asof.is/claim/clm_1C02430C4950, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915034919/0001104659-15-034919-index.htm.","url":"https://asof.is/claim/clm_1C02430C4950","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,292,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1C02430C4950","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-06"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 4,897,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_217D209218A4, https://asof.is/claim/clm_217D209218A4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915034919/0001104659-15-034919-index.htm.","url":"https://asof.is/claim/clm_217D209218A4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,897,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_217D209218A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2015, filed 2015-05-06"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 43,095,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_32CF94AF39DB, https://asof.is/claim/clm_32CF94AF39DB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915034919/0001104659-15-034919-index.htm.","url":"https://asof.is/claim/clm_32CF94AF39DB","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"43,095,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_32CF94AF39DB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2015, filed 2015-05-06"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 610,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_93E168E8343C, https://asof.is/claim/clm_93E168E8343C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915034919/0001104659-15-034919-index.htm.","url":"https://asof.is/claim/clm_93E168E8343C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"610,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_93E168E8343C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-06"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,488,757,318 shares\", as of 2015-03-31 (until 2015-06-30). Claim clm_B73D3A7A5FA7, https://asof.is/claim/clm_B73D3A7A5FA7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915034919/0001104659-15-034919-index.htm.","url":"https://asof.is/claim/clm_B73D3A7A5FA7","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,488,757,318 shares","status":"superseded","assertable":true,"id":"clm_B73D3A7A5FA7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2015, filed 2015-05-06"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 21,874,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_B7BFE3FD70B5, https://asof.is/claim/clm_B7BFE3FD70B5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915034919/0001104659-15-034919-index.htm.","url":"https://asof.is/claim/clm_B7BFE3FD70B5","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"21,874,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B7BFE3FD70B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2015, filed 2015-05-06"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,226,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_FF3EC9A8A46B, https://asof.is/claim/clm_FF3EC9A8A46B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915034919/0001104659-15-034919-index.htm.","url":"https://asof.is/claim/clm_FF3EC9A8A46B","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,226,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FF3EC9A8A46B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2015, filed 2015-05-06"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,170,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_1E113FF89F7B, https://asof.is/claim/clm_1E113FF89F7B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915055905/0001104659-15-055905-index.htm.","url":"https://asof.is/claim/clm_1E113FF89F7B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,170,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E113FF89F7B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,490,441,465 shares\", as of 2015-06-30 (until 2015-09-30). Claim clm_771836F657A2, https://asof.is/claim/clm_771836F657A2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915055905/0001104659-15-055905-index.htm.","url":"https://asof.is/claim/clm_771836F657A2","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,490,441,465 shares","status":"superseded","assertable":true,"id":"clm_771836F657A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 44,125,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_BFEBD87BE412, https://asof.is/claim/clm_BFEBD87BE412, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915055905/0001104659-15-055905-index.htm.","url":"https://asof.is/claim/clm_BFEBD87BE412","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"44,125,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BFEBD87BE412","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 784,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_C09A927BCCDA, https://asof.is/claim/clm_C09A927BCCDA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915055905/0001104659-15-055905-index.htm.","url":"https://asof.is/claim/clm_C09A927BCCDA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"784,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C09A927BCCDA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 23,008,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_D8D7C2D39205, https://asof.is/claim/clm_D8D7C2D39205, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915055905/0001104659-15-055905-index.htm.","url":"https://asof.is/claim/clm_D8D7C2D39205","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"23,008,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D8D7C2D39205","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 729,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_E789F7FC62E7, https://asof.is/claim/clm_E789F7FC62E7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915055905/0001104659-15-055905-index.htm.","url":"https://asof.is/claim/clm_E789F7FC62E7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"729,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E789F7FC62E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,048,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_E79667D75AE6, https://asof.is/claim/clm_E79667D75AE6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915055905/0001104659-15-055905-index.htm.","url":"https://asof.is/claim/clm_E79667D75AE6","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,048,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E79667D75AE6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2015, filed 2015-08-04"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 713,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_0E1A644D6289, https://asof.is/claim/clm_0E1A644D6289, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915076189/0001104659-15-076189-index.htm.","url":"https://asof.is/claim/clm_0E1A644D6289","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"713,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0E1A644D6289","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,132,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_278DC080FBE9, https://asof.is/claim/clm_278DC080FBE9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915076189/0001104659-15-076189-index.htm.","url":"https://asof.is/claim/clm_278DC080FBE9","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,132,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_278DC080FBE9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 21,111,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_32290A5FC0E4, https://asof.is/claim/clm_32290A5FC0E4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915076189/0001104659-15-076189-index.htm.","url":"https://asof.is/claim/clm_32290A5FC0E4","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"21,111,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_32290A5FC0E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,150,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_4DDA3D71417E, https://asof.is/claim/clm_4DDA3D71417E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915076189/0001104659-15-076189-index.htm.","url":"https://asof.is/claim/clm_4DDA3D71417E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,150,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4DDA3D71417E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 41,725,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_5EAB483532A7, https://asof.is/claim/clm_5EAB483532A7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915076189/0001104659-15-076189-index.htm.","url":"https://asof.is/claim/clm_5EAB483532A7","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"41,725,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5EAB483532A7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 580,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_94B13D450A74, https://asof.is/claim/clm_94B13D450A74, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915076189/0001104659-15-076189-index.htm.","url":"https://asof.is/claim/clm_94B13D450A74","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"580,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94B13D450A74","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-30","until":"2016-01-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,491,719,891 shares\", as of 2015-09-30 (until 2016-01-31). Claim clm_96EE5B28A5A8, https://asof.is/claim/clm_96EE5B28A5A8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465915076189/0001104659-15-076189-index.htm.","url":"https://asof.is/claim/clm_96EE5B28A5A8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,491,719,891 shares","status":"superseded","assertable":true,"id":"clm_96EE5B28A5A8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 20,405,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_16E555E53E25, https://asof.is/claim/clm_16E555E53E25, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/0001047469-16-010246-index.htm.","url":"https://asof.is/claim/clm_16E555E53E25","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"20,405,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_16E555E53E25","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 21,211,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_2369723DE4DA, https://asof.is/claim/clm_2369723DE4DA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/0001047469-16-010246-index.htm.","url":"https://asof.is/claim/clm_2369723DE4DA","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"21,211,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2369723DE4DA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 41,247,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_4DAF27B7700C, https://asof.is/claim/clm_4DAF27B7700C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/0001047469-16-010246-index.htm.","url":"https://asof.is/claim/clm_4DAF27B7700C","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"41,247,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4DAF27B7700C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 2,867,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_D45686CBE9CE, https://asof.is/claim/clm_D45686CBE9CE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/0001047469-16-010246-index.htm.","url":"https://asof.is/claim/clm_D45686CBE9CE","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"2,867,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D45686CBE9CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 4,423,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_E00F0EE99100, https://asof.is/claim/clm_E00F0EE99100, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/0001047469-16-010246-index.htm.","url":"https://asof.is/claim/clm_E00F0EE99100","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,423,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E00F0EE99100","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 5,001,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_E25A94C67D09, https://asof.is/claim/clm_E25A94C67D09, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/0001047469-16-010246-index.htm.","url":"https://asof.is/claim/clm_E25A94C67D09","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,001,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E25A94C67D09","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2015, filed 2016-02-19"}},{"date":"2016-01-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,473,241,861 shares\", as of 2016-01-31 (until 2016-03-31). Claim clm_1B44F2DE8736, https://asof.is/claim/clm_1B44F2DE8736, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/0001047469-16-010246-index.htm.","url":"https://asof.is/claim/clm_1B44F2DE8736","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,473,241,861 shares","status":"superseded","assertable":true,"id":"clm_1B44F2DE8736","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2015, filed 2016-02-19"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 316,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_0603855B1B45, https://asof.is/claim/clm_0603855B1B45, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916117710/0001104659-16-117710-index.htm.","url":"https://asof.is/claim/clm_0603855B1B45","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"316,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0603855B1B45","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-04"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,334,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_1FC299F54EDD, https://asof.is/claim/clm_1FC299F54EDD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916117710/0001104659-16-117710-index.htm.","url":"https://asof.is/claim/clm_1FC299F54EDD","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,334,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1FC299F54EDD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2016, filed 2016-05-04"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 4,885,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_33CB344232AF, https://asof.is/claim/clm_33CB344232AF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916117710/0001104659-16-117710-index.htm.","url":"https://asof.is/claim/clm_33CB344232AF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,885,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_33CB344232AF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2016, filed 2016-05-04"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 524,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_386CF61547F5, https://asof.is/claim/clm_386CF61547F5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916117710/0001104659-16-117710-index.htm.","url":"https://asof.is/claim/clm_386CF61547F5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"524,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_386CF61547F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-04"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 20,722,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_9E0E24B3E644, https://asof.is/claim/clm_9E0E24B3E644, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916117710/0001104659-16-117710-index.htm.","url":"https://asof.is/claim/clm_9E0E24B3E644","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"20,722,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9E0E24B3E644","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2016, filed 2016-05-04"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 39,637,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_A72DE3456A35, https://asof.is/claim/clm_A72DE3456A35, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916117710/0001104659-16-117710-index.htm.","url":"https://asof.is/claim/clm_A72DE3456A35","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"39,637,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A72DE3456A35","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2016, filed 2016-05-04"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,469,152,033 shares\", as of 2016-03-31 (until 2016-06-30). Claim clm_E22E26C7A5C9, https://asof.is/claim/clm_E22E26C7A5C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916117710/0001104659-16-117710-index.htm.","url":"https://asof.is/claim/clm_E22E26C7A5C9","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,469,152,033 shares","status":"superseded","assertable":true,"id":"clm_E22E26C7A5C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2016, filed 2016-05-04"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 20,675,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_08EC8818E782, https://asof.is/claim/clm_08EC8818E782, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916136572/0001104659-16-136572-index.htm.","url":"https://asof.is/claim/clm_08EC8818E782","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"20,675,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_08EC8818E782","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2016, filed 2016-08-03"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,333,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_1B83117F5484, https://asof.is/claim/clm_1B83117F5484, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916136572/0001104659-16-136572-index.htm.","url":"https://asof.is/claim/clm_1B83117F5484","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,333,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1B83117F5484","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2016, filed 2016-08-03"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 39,831,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_2A02207F2DFC, https://asof.is/claim/clm_2A02207F2DFC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916136572/0001104659-16-136572-index.htm.","url":"https://asof.is/claim/clm_2A02207F2DFC","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"39,831,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2A02207F2DFC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2016, filed 2016-08-03"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 816,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_3ED6D1E2F97A, https://asof.is/claim/clm_3ED6D1E2F97A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916136572/0001104659-16-136572-index.htm.","url":"https://asof.is/claim/clm_3ED6D1E2F97A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"816,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3ED6D1E2F97A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-03"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,469,995,415 shares\", as of 2016-06-30 (until 2016-09-30). Claim clm_9FA1445E4402, https://asof.is/claim/clm_9FA1445E4402, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916136572/0001104659-16-136572-index.htm.","url":"https://asof.is/claim/clm_9FA1445E4402","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,469,995,415 shares","status":"superseded","assertable":true,"id":"clm_9FA1445E4402","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2016, filed 2016-08-03"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 615,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_D6BBD632FF41, https://asof.is/claim/clm_D6BBD632FF41, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916136572/0001104659-16-136572-index.htm.","url":"https://asof.is/claim/clm_D6BBD632FF41","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"615,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D6BBD632FF41","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-03"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 2,578,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_FA8D28D995F1, https://asof.is/claim/clm_FA8D28D995F1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916136572/0001104659-16-136572-index.htm.","url":"https://asof.is/claim/clm_FA8D28D995F1","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,578,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FA8D28D995F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2016, filed 2016-08-03"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 897,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_193539EFFD26, https://asof.is/claim/clm_193539EFFD26, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916154583/0001104659-16-154583-index.htm.","url":"https://asof.is/claim/clm_193539EFFD26","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"897,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_193539EFFD26","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-03"}},{"date":"2016-09-30","until":"2017-01-31","published":"2016-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,472,309,523 shares\", as of 2016-09-30 (until 2017-01-31). Claim clm_20D5B4C10A23, https://asof.is/claim/clm_20D5B4C10A23, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916154583/0001104659-16-154583-index.htm.","url":"https://asof.is/claim/clm_20D5B4C10A23","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,472,309,523 shares","status":"superseded","assertable":true,"id":"clm_20D5B4C10A23","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2016, filed 2016-11-03"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 39,497,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_4DB8B69673CB, https://asof.is/claim/clm_4DB8B69673CB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916154583/0001104659-16-154583-index.htm.","url":"https://asof.is/claim/clm_4DB8B69673CB","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"39,497,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4DB8B69673CB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2016, filed 2016-11-03"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: -329,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_5F39464983EE, https://asof.is/claim/clm_5F39464983EE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916154583/0001104659-16-154583-index.htm.","url":"https://asof.is/claim/clm_5F39464983EE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-329,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5F39464983EE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-03"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 2,500,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_6E48EACB3253, https://asof.is/claim/clm_6E48EACB3253, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916154583/0001104659-16-154583-index.htm.","url":"https://asof.is/claim/clm_6E48EACB3253","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,500,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E48EACB3253","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2016, filed 2016-11-03"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 5,302,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_8064646C7C6E, https://asof.is/claim/clm_8064646C7C6E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916154583/0001104659-16-154583-index.htm.","url":"https://asof.is/claim/clm_8064646C7C6E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,302,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8064646C7C6E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2016, filed 2016-11-03"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 20,776,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_F5A188432375, https://asof.is/claim/clm_F5A188432375, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465916154583/0001104659-16-154583-index.htm.","url":"https://asof.is/claim/clm_F5A188432375","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"20,776,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F5A188432375","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2016, filed 2016-11-03"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 52,666,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_152F5F758C41, https://asof.is/claim/clm_152F5F758C41, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746917000744/0001047469-17-000744-index.htm.","url":"https://asof.is/claim/clm_152F5F758C41","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"52,666,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_152F5F758C41","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-12-31","until":"2017-12-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 20,853,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_305771785CD8, https://asof.is/claim/clm_305771785CD8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_305771785CD8","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"20,853,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_305771785CD8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2018, filed 2019-02-22"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 18,620,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_30F5C427EA78, https://asof.is/claim/clm_30F5C427EA78, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746917000744/0001047469-17-000744-index.htm.","url":"https://asof.is/claim/clm_30F5C427EA78","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"18,620,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_30F5C427EA78","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 3,185,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_476A660B6C4B, https://asof.is/claim/clm_476A660B6C4B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746917000744/0001047469-17-000744-index.htm.","url":"https://asof.is/claim/clm_476A660B6C4B","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"3,185,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_476A660B6C4B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 20,538,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_8210275EABD7, https://asof.is/claim/clm_8210275EABD7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746917000744/0001047469-17-000744-index.htm.","url":"https://asof.is/claim/clm_8210275EABD7","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"20,538,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8210275EABD7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 1,400,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_87CC51296794, https://asof.is/claim/clm_87CC51296794, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746917000744/0001047469-17-000744-index.htm.","url":"https://asof.is/claim/clm_87CC51296794","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"1,400,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_87CC51296794","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-17"}},{"date":"2017-01-31","until":"2017-03-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,727,997,596 shares\", as of 2017-01-31 (until 2017-03-31). Claim clm_D91F2017CC04, https://asof.is/claim/clm_D91F2017CC04, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746917000744/0001047469-17-000744-index.htm.","url":"https://asof.is/claim/clm_D91F2017CC04","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,727,997,596 shares","status":"superseded","assertable":true,"id":"clm_D91F2017CC04","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2016, filed 2017-02-17"}},{"date":"2017-03-31","until":"2017-06-30","published":"2018-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 6,335,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_15BAEA02B893, https://asof.is/claim/clm_15BAEA02B893, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm.","url":"https://asof.is/claim/clm_15BAEA02B893","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,335,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_15BAEA02B893","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2018, filed 2018-05-02"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,735,272,054 shares\", as of 2017-03-31 (until 2017-06-30). Claim clm_301BDC9105FC, https://asof.is/claim/clm_301BDC9105FC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917029430/0001104659-17-029430-index.htm.","url":"https://asof.is/claim/clm_301BDC9105FC","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,735,272,054 shares","status":"superseded","assertable":true,"id":"clm_301BDC9105FC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2017, filed 2017-05-03"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 8,706,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_437931E6A03A, https://asof.is/claim/clm_437931E6A03A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917029430/0001104659-17-029430-index.htm.","url":"https://asof.is/claim/clm_437931E6A03A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,706,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_437931E6A03A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2017, filed 2017-05-03"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: -202,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_47108AC0E4BE, https://asof.is/claim/clm_47108AC0E4BE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917029430/0001104659-17-029430-index.htm.","url":"https://asof.is/claim/clm_47108AC0E4BE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"-202,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_47108AC0E4BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-03"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 31,362,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_B7DCB616777F, https://asof.is/claim/clm_B7DCB616777F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917029430/0001104659-17-029430-index.htm.","url":"https://asof.is/claim/clm_B7DCB616777F","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,362,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B7DCB616777F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2017, filed 2017-05-03"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 419,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_DD829B82B38C, https://asof.is/claim/clm_DD829B82B38C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917029430/0001104659-17-029430-index.htm.","url":"https://asof.is/claim/clm_DD829B82B38C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"419,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD829B82B38C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-03"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 70,887,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_FFC8F38C32CB, https://asof.is/claim/clm_FFC8F38C32CB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917029430/0001104659-17-029430-index.htm.","url":"https://asof.is/claim/clm_FFC8F38C32CB","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"70,887,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FFC8F38C32CB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2017, filed 2017-05-03"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,737,443,264 shares\", as of 2017-06-30 (until 2017-09-30). Claim clm_0F510C806C66, https://asof.is/claim/clm_0F510C806C66, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917048855/0001104659-17-048855-index.htm.","url":"https://asof.is/claim/clm_0F510C806C66","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,737,443,264 shares","status":"superseded","assertable":true,"id":"clm_0F510C806C66","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2017, filed 2017-08-02"}},{"date":"2017-06-30","until":"2017-09-30","published":"2018-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 6,637,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_29C8A48CFFA6, https://asof.is/claim/clm_29C8A48CFFA6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm.","url":"https://asof.is/claim/clm_29C8A48CFFA6","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,637,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_29C8A48CFFA6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2018, filed 2018-08-01"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 427,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_2BF64D8B9D86, https://asof.is/claim/clm_2BF64D8B9D86, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917048855/0001104659-17-048855-index.htm.","url":"https://asof.is/claim/clm_2BF64D8B9D86","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"427,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2BF64D8B9D86","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-02"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 283,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_77D0019EBF2D, https://asof.is/claim/clm_77D0019EBF2D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917048855/0001104659-17-048855-index.htm.","url":"https://asof.is/claim/clm_77D0019EBF2D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"283,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_77D0019EBF2D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-02"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 9,675,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_83F1FF1326CA, https://asof.is/claim/clm_83F1FF1326CA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917048855/0001104659-17-048855-index.htm.","url":"https://asof.is/claim/clm_83F1FF1326CA","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,675,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_83F1FF1326CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2017, filed 2017-08-02"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 71,151,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_CDC7CB62542B, https://asof.is/claim/clm_CDC7CB62542B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917048855/0001104659-17-048855-index.htm.","url":"https://asof.is/claim/clm_CDC7CB62542B","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"71,151,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CDC7CB62542B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2017, filed 2017-08-02"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 31,602,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_E37A9F632E3D, https://asof.is/claim/clm_E37A9F632E3D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917048855/0001104659-17-048855-index.htm.","url":"https://asof.is/claim/clm_E37A9F632E3D","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,602,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E37A9F632E3D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2017, filed 2017-08-02"}},{"date":"2017-09-30","until":"2018-01-31","published":"2017-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,740,600,687 shares\", as of 2017-09-30 (until 2018-01-31). Claim clm_00A19041C7EC, https://asof.is/claim/clm_00A19041C7EC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917065654/0001104659-17-065654-index.htm.","url":"https://asof.is/claim/clm_00A19041C7EC","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,740,600,687 shares","status":"superseded","assertable":true,"id":"clm_00A19041C7EC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2017, filed 2017-11-02"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 72,248,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_129A9E1E6676, https://asof.is/claim/clm_129A9E1E6676, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917065654/0001104659-17-065654-index.htm.","url":"https://asof.is/claim/clm_129A9E1E6676","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"72,248,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_129A9E1E6676","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2017, filed 2017-11-02"}},{"date":"2017-09-30","until":"2018-03-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 6,829,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_402A58FFA584, https://asof.is/claim/clm_402A58FFA584, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm.","url":"https://asof.is/claim/clm_402A58FFA584","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,829,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_402A58FFA584","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 603,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_4061F715D3A7, https://asof.is/claim/clm_4061F715D3A7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917065654/0001104659-17-065654-index.htm.","url":"https://asof.is/claim/clm_4061F715D3A7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"603,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4061F715D3A7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-02"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 11,012,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_4689BDC0942B, https://asof.is/claim/clm_4689BDC0942B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917065654/0001104659-17-065654-index.htm.","url":"https://asof.is/claim/clm_4689BDC0942B","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"11,012,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4689BDC0942B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2017, filed 2017-11-02"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 810,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_77913BAAC587, https://asof.is/claim/clm_77913BAAC587, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917065654/0001104659-17-065654-index.htm.","url":"https://asof.is/claim/clm_77913BAAC587","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"810,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_77913BAAC587","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-02"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 32,032,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_E93715A27F70, https://asof.is/claim/clm_E93715A27F70, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465917065654/0001104659-17-065654-index.htm.","url":"https://asof.is/claim/clm_E93715A27F70","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"32,032,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E93715A27F70","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2017, filed 2017-11-02"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 477,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_0E0A2ADD6C11, https://asof.is/claim/clm_0E0A2ADD6C11, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746918000856/0001047469-18-000856-index.htm.","url":"https://asof.is/claim/clm_0E0A2ADD6C11","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"477,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0E0A2ADD6C11","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 9,407,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_3F95EE2FABBF, https://asof.is/claim/clm_3F95EE2FABBF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746918000856/0001047469-18-000856-index.htm.","url":"https://asof.is/claim/clm_3F95EE2FABBF","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,407,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3F95EE2FABBF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 1,726,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_4420320133D9, https://asof.is/claim/clm_4420320133D9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746918000856/0001047469-18-000856-index.htm.","url":"https://asof.is/claim/clm_4420320133D9","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"1,726,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4420320133D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 76,250,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_60A75BEF73AA, https://asof.is/claim/clm_60A75BEF73AA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746918000856/0001047469-18-000856-index.htm.","url":"https://asof.is/claim/clm_60A75BEF73AA","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"76,250,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_60A75BEF73AA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 30,897,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_9D7A48D859AE, https://asof.is/claim/clm_9D7A48D859AE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746918000856/0001047469-18-000856-index.htm.","url":"https://asof.is/claim/clm_9D7A48D859AE","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"30,897,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9D7A48D859AE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,260,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_B40728D6F627, https://asof.is/claim/clm_B40728D6F627, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_B40728D6F627","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,260,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B40728D6F627","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-21"}},{"date":"2017-12-31","until":"2018-12-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 27,390,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_CBCFC23B00BC, https://asof.is/claim/clm_CBCFC23B00BC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_CBCFC23B00BC","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"27,390,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CBCFC23B00BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2018, filed 2019-02-22"}},{"date":"2018-01-31","until":"2018-03-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,746,333,892 shares\", as of 2018-01-31 (until 2018-03-31). Claim clm_749951A1C0C9, https://asof.is/claim/clm_749951A1C0C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746918000856/0001047469-18-000856-index.htm.","url":"https://asof.is/claim/clm_749951A1C0C9","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,746,333,892 shares","status":"superseded","assertable":true,"id":"clm_749951A1C0C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2017, filed 2018-02-16"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 418,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_32DA1D18D30F, https://asof.is/claim/clm_32DA1D18D30F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm.","url":"https://asof.is/claim/clm_32DA1D18D30F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"418,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_32DA1D18D30F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-02"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 608,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_455364238A9E, https://asof.is/claim/clm_455364238A9E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm.","url":"https://asof.is/claim/clm_455364238A9E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"608,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_455364238A9E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-02"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,753,187,766 shares\", as of 2018-03-31 (until 2018-06-30). Claim clm_4A012C69AC0E, https://asof.is/claim/clm_4A012C69AC0E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm.","url":"https://asof.is/claim/clm_4A012C69AC0E","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,753,187,766 shares","status":"superseded","assertable":true,"id":"clm_4A012C69AC0E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2018, filed 2018-05-02"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,857,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_59EC592653CE, https://asof.is/claim/clm_59EC592653CE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm.","url":"https://asof.is/claim/clm_59EC592653CE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,857,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_59EC592653CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2018, filed 2018-05-02"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 70,908,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_A40F2BAB5CB1, https://asof.is/claim/clm_A40F2BAB5CB1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm.","url":"https://asof.is/claim/clm_A40F2BAB5CB1","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"70,908,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A40F2BAB5CB1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2018, filed 2018-05-02"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,390,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_C3C0F612B29F, https://asof.is/claim/clm_C3C0F612B29F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm.","url":"https://asof.is/claim/clm_C3C0F612B29F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,390,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C3C0F612B29F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2018, filed 2018-05-02"}},{"date":"2018-03-31","until":"2018-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 589,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_D0387CB879C0, https://asof.is/claim/clm_D0387CB879C0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_D0387CB879C0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"589,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D0387CB879C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 31,399,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_D7620A7ABE34, https://asof.is/claim/clm_D7620A7ABE34, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm.","url":"https://asof.is/claim/clm_D7620A7ABE34","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,399,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D7620A7ABE34","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2018, filed 2018-05-02"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 882,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_3F5036ACEF86, https://asof.is/claim/clm_3F5036ACEF86, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm.","url":"https://asof.is/claim/clm_3F5036ACEF86","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"882,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3F5036ACEF86","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-01"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 68,415,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_4B97A512CC39, https://asof.is/claim/clm_4B97A512CC39, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm.","url":"https://asof.is/claim/clm_4B97A512CC39","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"68,415,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4B97A512CC39","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2018, filed 2018-08-01"}},{"date":"2018-06-30","until":"2018-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 575,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_6B0B3077A414, https://asof.is/claim/clm_6B0B3077A414, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_6B0B3077A414","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"575,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6B0B3077A414","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,767,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_79374FAAB118, https://asof.is/claim/clm_79374FAAB118, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm.","url":"https://asof.is/claim/clm_79374FAAB118","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,767,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_79374FAAB118","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2018, filed 2018-08-01"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 30,577,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_9C4568F5F599, https://asof.is/claim/clm_9C4568F5F599, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm.","url":"https://asof.is/claim/clm_9C4568F5F599","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"30,577,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9C4568F5F599","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2018, filed 2018-08-01"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,754,319,284 shares\", as of 2018-06-30 (until 2018-09-30). Claim clm_9F7DBFC910F0, https://asof.is/claim/clm_9F7DBFC910F0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm.","url":"https://asof.is/claim/clm_9F7DBFC910F0","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,754,319,284 shares","status":"superseded","assertable":true,"id":"clm_9F7DBFC910F0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2018, filed 2018-08-01"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,065,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_E32F9485C0C9, https://asof.is/claim/clm_E32F9485C0C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm.","url":"https://asof.is/claim/clm_E32F9485C0C9","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,065,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E32F9485C0C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2018, filed 2018-08-01"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 733,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_EA6CC4097E8D, https://asof.is/claim/clm_EA6CC4097E8D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm.","url":"https://asof.is/claim/clm_EA6CC4097E8D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"733,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EA6CC4097E8D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-01"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 71,637,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_3B31ADE89C36, https://asof.is/claim/clm_3B31ADE89C36, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm.","url":"https://asof.is/claim/clm_3B31ADE89C36","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"71,637,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3B31ADE89C36","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 30,705,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_3FB8E64381F1, https://asof.is/claim/clm_3FB8E64381F1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm.","url":"https://asof.is/claim/clm_3FB8E64381F1","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"30,705,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3FB8E64381F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2019-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 574,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_41B5CF7870D0, https://asof.is/claim/clm_41B5CF7870D0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_41B5CF7870D0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"574,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_41B5CF7870D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2018-09-30","until":"2019-01-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,756,333,032 shares\", as of 2018-09-30 (until 2019-01-31). Claim clm_66C9CF7C9C4F, https://asof.is/claim/clm_66C9CF7C9C4F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm.","url":"https://asof.is/claim/clm_66C9CF7C9C4F","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,756,333,032 shares","status":"superseded","assertable":true,"id":"clm_66C9CF7C9C4F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,369,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_6AD344300D4A, https://asof.is/claim/clm_6AD344300D4A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm.","url":"https://asof.is/claim/clm_6AD344300D4A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,369,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6AD344300D4A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 995,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_A2F6D8E3F671, https://asof.is/claim/clm_A2F6D8E3F671, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm.","url":"https://asof.is/claim/clm_A2F6D8E3F671","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"995,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A2F6D8E3F671","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,656,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_DE1BAF682D4F, https://asof.is/claim/clm_DE1BAF682D4F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm.","url":"https://asof.is/claim/clm_DE1BAF682D4F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,656,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DE1BAF682D4F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 563,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_EA18E0C4D59D, https://asof.is/claim/clm_EA18E0C4D59D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm.","url":"https://asof.is/claim/clm_EA18E0C4D59D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"563,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EA18E0C4D59D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-12-31","until":"2019-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,300,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_0556A1975396, https://asof.is/claim/clm_0556A1975396, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_0556A1975396","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,300,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0556A1975396","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-21"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 67,173,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_1558E1C3AC44, https://asof.is/claim/clm_1558E1C3AC44, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_1558E1C3AC44","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"67,173,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1558E1C3AC44","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2018, filed 2019-02-22"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 2,368,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_431C6CD455C6, https://asof.is/claim/clm_431C6CD455C6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_431C6CD455C6","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"2,368,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_431C6CD455C6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2018, filed 2019-02-22"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 3,650,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_B2ED5C0080DE, https://asof.is/claim/clm_B2ED5C0080DE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_B2ED5C0080DE","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"3,650,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B2ED5C0080DE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2018, filed 2019-02-22"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 30,578,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_B704D1D4A319, https://asof.is/claim/clm_B704D1D4A319, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_B704D1D4A319","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"30,578,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B704D1D4A319","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2018, filed 2019-02-22"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,844,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_CAD5272C9D86, https://asof.is/claim/clm_CAD5272C9D86, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_CAD5272C9D86","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,844,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CAD5272C9D86","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2018, filed 2019-02-22"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 30,524,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_CD188CE803B5, https://asof.is/claim/clm_CD188CE803B5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_CD188CE803B5","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"30,524,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CD188CE803B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2018, filed 2019-02-22"}},{"date":"2019-01-31","until":"2019-03-31","published":"2019-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,756,470,269 shares\", as of 2019-01-31 (until 2019-03-31). Claim clm_2216B46B8180, https://asof.is/claim/clm_2216B46B8180, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm.","url":"https://asof.is/claim/clm_2216B46B8180","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,756,470,269 shares","status":"superseded","assertable":true,"id":"clm_2216B46B8180","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2018, filed 2019-02-22"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,022,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_166B1C725C2A, https://asof.is/claim/clm_166B1C725C2A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_166B1C725C2A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,022,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_166B1C725C2A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 672,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_235E5A9BD334, https://asof.is/claim/clm_235E5A9BD334, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_235E5A9BD334","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"672,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_235E5A9BD334","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,764,181,262 shares\", as of 2019-03-31 (until 2019-06-30). Claim clm_24ACD32E0696, https://asof.is/claim/clm_24ACD32E0696, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_24ACD32E0696","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,764,181,262 shares","status":"superseded","assertable":true,"id":"clm_24ACD32E0696","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 67,610,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_6BF87C6DF992, https://asof.is/claim/clm_6BF87C6DF992, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_6BF87C6DF992","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"67,610,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6BF87C6DF992","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 30,925,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_7D62673F73F6, https://asof.is/claim/clm_7D62673F73F6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_7D62673F73F6","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"30,925,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D62673F73F6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 672,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_7FCB849C8A66, https://asof.is/claim/clm_7FCB849C8A66, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_7FCB849C8A66","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"672,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7FCB849C8A66","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 739,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_8F33F13465E8, https://asof.is/claim/clm_8F33F13465E8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_8F33F13465E8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"739,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F33F13465E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,535,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_C0322CACEF5F, https://asof.is/claim/clm_C0322CACEF5F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm.","url":"https://asof.is/claim/clm_C0322CACEF5F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,535,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C0322CACEF5F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,206,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_2F19688C782C, https://asof.is/claim/clm_2F19688C782C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_2F19688C782C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,206,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F19688C782C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,767,397,615 shares\", as of 2019-06-30 (until 2019-09-30). Claim clm_8048076BF037, https://asof.is/claim/clm_8048076BF037, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_8048076BF037","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,767,397,615 shares","status":"superseded","assertable":true,"id":"clm_8048076BF037","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 68,427,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_B5CB1DFE9334, https://asof.is/claim/clm_B5CB1DFE9334, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_B5CB1DFE9334","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"68,427,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B5CB1DFE9334","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 31,686,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_B94747095EFB, https://asof.is/claim/clm_B94747095EFB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_B94747095EFB","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,686,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B94747095EFB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,979,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_BDDE4A079F3F, https://asof.is/claim/clm_BDDE4A079F3F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_BDDE4A079F3F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,979,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BDDE4A079F3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 577,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_C910D6802F6E, https://asof.is/claim/clm_C910D6802F6E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_C910D6802F6E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"577,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C910D6802F6E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,006,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_CEF1F2D39061, https://asof.is/claim/clm_CEF1F2D39061, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_CEF1F2D39061","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,006,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CEF1F2D39061","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,137,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_D60E926E5D8D, https://asof.is/claim/clm_D60E926E5D8D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm.","url":"https://asof.is/claim/clm_D60E926E5D8D","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,137,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D60E926E5D8D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-09-30","until":"2020-01-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,768,455,705 shares\", as of 2019-09-30 (until 2020-01-31). Claim clm_18993939AE37, https://asof.is/claim/clm_18993939AE37, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_18993939AE37","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,768,455,705 shares","status":"superseded","assertable":true,"id":"clm_18993939AE37","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 68,539,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_272419186E81, https://asof.is/claim/clm_272419186E81, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_272419186E81","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"68,539,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_272419186E81","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 31,817,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_6AC71DAEDCE7, https://asof.is/claim/clm_6AC71DAEDCE7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_6AC71DAEDCE7","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,817,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6AC71DAEDCE7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 8,076,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_6EA4DA762D97, https://asof.is/claim/clm_6EA4DA762D97, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_6EA4DA762D97","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,076,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6EA4DA762D97","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,198,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_79BB0F5ED4DC, https://asof.is/claim/clm_79BB0F5ED4DC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_79BB0F5ED4DC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,198,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_79BB0F5ED4DC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,091,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_D5F76318A6D2, https://asof.is/claim/clm_D5F76318A6D2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_D5F76318A6D2","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,091,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D5F76318A6D2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 596,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_D72480210DBD, https://asof.is/claim/clm_D72480210DBD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_D72480210DBD","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"596,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D72480210DBD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 960,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_E5DF870B61C4, https://asof.is/claim/clm_E5DF870B61C4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm.","url":"https://asof.is/claim/clm_E5DF870B61C4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"960,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E5DF870B61C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2019, filed 2019-10-31"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 31,088,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_1226C199906C, https://asof.is/claim/clm_1226C199906C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_1226C199906C","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,088,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1226C199906C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 31,904,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_1395DECF0604, https://asof.is/claim/clm_1395DECF0604, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_1395DECF0604","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"31,904,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1395DECF0604","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 67,887,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_13B501924E09, https://asof.is/claim/clm_13B501924E09, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_13B501924E09","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"67,887,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_13B501924E09","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 4,532,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_50D9545CB1D5, https://asof.is/claim/clm_50D9545CB1D5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_50D9545CB1D5","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"4,532,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_50D9545CB1D5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,860,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_6379D6E6764E, https://asof.is/claim/clm_6379D6E6764E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_6379D6E6764E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,860,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6379D6E6764E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 3,687,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_82D437604E1A, https://asof.is/claim/clm_82D437604E1A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_82D437604E1A","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"3,687,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_82D437604E1A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,440,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_E3A1981FFAA1, https://asof.is/claim/clm_E3A1981FFAA1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_E3A1981FFAA1","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,440,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E3A1981FFAA1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-21"}},{"date":"2020-01-31","until":"2020-03-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,763,433,243 shares\", as of 2020-01-31 (until 2020-03-31). Claim clm_4CC142CFD436, https://asof.is/claim/clm_4CC142CFD436, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm.","url":"https://asof.is/claim/clm_4CC142CFD436","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,763,433,243 shares","status":"superseded","assertable":true,"id":"clm_4CC142CFD436","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2019, filed 2020-02-21"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,726,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_0C0541A5EB25, https://asof.is/claim/clm_0C0541A5EB25, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm.","url":"https://asof.is/claim/clm_0C0541A5EB25","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,726,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0C0541A5EB25","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2020, filed 2020-04-29"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 30,218,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_178BA35B231F, https://asof.is/claim/clm_178BA35B231F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm.","url":"https://asof.is/claim/clm_178BA35B231F","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"30,218,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_178BA35B231F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2020, filed 2020-04-29"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,768,845,326 shares\", as of 2020-03-31 (until 2020-06-30). Claim clm_321196ABECC8, https://asof.is/claim/clm_321196ABECC8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm.","url":"https://asof.is/claim/clm_321196ABECC8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,768,845,326 shares","status":"superseded","assertable":true,"id":"clm_321196ABECC8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2020, filed 2020-04-29"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 564,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_3BBCD8D2245C, https://asof.is/claim/clm_3BBCD8D2245C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm.","url":"https://asof.is/claim/clm_3BBCD8D2245C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"564,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3BBCD8D2245C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2020, filed 2020-04-29"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 578,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_5BDD75D9E730, https://asof.is/claim/clm_5BDD75D9E730, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm.","url":"https://asof.is/claim/clm_5BDD75D9E730","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"578,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5BDD75D9E730","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2020, filed 2020-04-29"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 3,377,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_9ABE667349AF, https://asof.is/claim/clm_9ABE667349AF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm.","url":"https://asof.is/claim/clm_9ABE667349AF","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,377,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9ABE667349AF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2020, filed 2020-04-29"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 66,777,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_A0B8EEF54F83, https://asof.is/claim/clm_A0B8EEF54F83, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm.","url":"https://asof.is/claim/clm_A0B8EEF54F83","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"66,777,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A0B8EEF54F83","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-04-29"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 758,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_E25EFE866047, https://asof.is/claim/clm_E25EFE866047, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm.","url":"https://asof.is/claim/clm_E25EFE866047","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"758,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E25EFE866047","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2020, filed 2020-04-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 537,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_095EBCF0260A, https://asof.is/claim/clm_095EBCF0260A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm.","url":"https://asof.is/claim/clm_095EBCF0260A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"537,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_095EBCF0260A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 30,578,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_1795E98E8729, https://asof.is/claim/clm_1795E98E8729, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm.","url":"https://asof.is/claim/clm_1795E98E8729","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"30,578,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1795E98E8729","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 68,776,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_36D0A18F3352, https://asof.is/claim/clm_36D0A18F3352, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm.","url":"https://asof.is/claim/clm_36D0A18F3352","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"68,776,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_36D0A18F3352","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,763,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_4B2593012B5B, https://asof.is/claim/clm_4B2593012B5B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm.","url":"https://asof.is/claim/clm_4B2593012B5B","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,763,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4B2593012B5B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 672,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_5F9689E3114D, https://asof.is/claim/clm_5F9689E3114D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm.","url":"https://asof.is/claim/clm_5F9689E3114D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"672,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5F9689E3114D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 7,328,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_9EA536FA1B5B, https://asof.is/claim/clm_9EA536FA1B5B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm.","url":"https://asof.is/claim/clm_9EA536FA1B5B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,328,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9EA536FA1B5B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,770,529,999 shares\", as of 2020-06-30 (until 2020-09-30). Claim clm_A9B16D8709AE, https://asof.is/claim/clm_A9B16D8709AE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm.","url":"https://asof.is/claim/clm_A9B16D8709AE","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,770,529,999 shares","status":"superseded","assertable":true,"id":"clm_A9B16D8709AE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 564,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_BB551BCBB517, https://asof.is/claim/clm_BB551BCBB517, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm.","url":"https://asof.is/claim/clm_BB551BCBB517","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"564,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BB551BCBB517","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,232,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_146580C19233, https://asof.is/claim/clm_146580C19233, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm.","url":"https://asof.is/claim/clm_146580C19233","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,232,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_146580C19233","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2021-01-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,772,361,581 shares\", as of 2020-09-30 (until 2021-01-31). Claim clm_2A5B8E7E3E6F, https://asof.is/claim/clm_2A5B8E7E3E6F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm.","url":"https://asof.is/claim/clm_2A5B8E7E3E6F","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,772,361,581 shares","status":"superseded","assertable":true,"id":"clm_2A5B8E7E3E6F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 31,386,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_2CE5107EE0B2, https://asof.is/claim/clm_2CE5107EE0B2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm.","url":"https://asof.is/claim/clm_2CE5107EE0B2","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"31,386,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2CE5107EE0B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 8,853,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_3B0F0FD9892A, https://asof.is/claim/clm_3B0F0FD9892A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm.","url":"https://asof.is/claim/clm_3B0F0FD9892A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,853,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3B0F0FD9892A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 69,043,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_4FE2013C1FF1, https://asof.is/claim/clm_4FE2013C1FF1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm.","url":"https://asof.is/claim/clm_4FE2013C1FF1","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"69,043,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4FE2013C1FF1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 580,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_5227340047B9, https://asof.is/claim/clm_5227340047B9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm.","url":"https://asof.is/claim/clm_5227340047B9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"580,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5227340047B9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,495,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_8501CF976D96, https://asof.is/claim/clm_8501CF976D96, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm.","url":"https://asof.is/claim/clm_8501CF976D96","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,495,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8501CF976D96","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,480,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_9F84425DB42F, https://asof.is/claim/clm_9F84425DB42F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm.","url":"https://asof.is/claim/clm_9F84425DB42F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,480,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9F84425DB42F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 5,357,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_3EFF550A655C, https://asof.is/claim/clm_3EFF550A655C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm.","url":"https://asof.is/claim/clm_3EFF550A655C","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"5,357,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3EFF550A655C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 4,495,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_492C7215F04B, https://asof.is/claim/clm_492C7215F04B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm.","url":"https://asof.is/claim/clm_492C7215F04B","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,495,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_492C7215F04B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,838,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_A8B28B659942, https://asof.is/claim/clm_A8B28B659942, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm.","url":"https://asof.is/claim/clm_A8B28B659942","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,838,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A8B28B659942","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 72,548,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_B337C7B6BC7D, https://asof.is/claim/clm_B337C7B6BC7D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm.","url":"https://asof.is/claim/clm_B337C7B6BC7D","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"72,548,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B337C7B6BC7D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 34,608,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_C6D9CE4452DC, https://asof.is/claim/clm_C6D9CE4452DC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm.","url":"https://asof.is/claim/clm_C6D9CE4452DC","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"34,608,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C6D9CE4452DC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,420,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_CCB485006F63, https://asof.is/claim/clm_CCB485006F63, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm.","url":"https://asof.is/claim/clm_CCB485006F63","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,420,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CCB485006F63","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 32,784,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_E91F357595A5, https://asof.is/claim/clm_E91F357595A5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm.","url":"https://asof.is/claim/clm_E91F357595A5","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"32,784,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E91F357595A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2020, filed 2021-02-19"}},{"date":"2021-01-31","until":"2021-03-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,771,529,358 shares\", as of 2021-01-31 (until 2021-03-31). Claim clm_826A1DC08AE8, https://asof.is/claim/clm_826A1DC08AE8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm.","url":"https://asof.is/claim/clm_826A1DC08AE8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,771,529,358 shares","status":"superseded","assertable":true,"id":"clm_826A1DC08AE8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2020, filed 2021-02-19"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,776,820,148 shares\", as of 2021-03-31 (until 2021-06-30). Claim clm_1F524FFD747D, https://asof.is/claim/clm_1F524FFD747D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_1F524FFD747D","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,776,820,148 shares","status":"superseded","assertable":true,"id":"clm_1F524FFD747D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2021, filed 2021-05-05"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 10,456,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_336AC8B041A1, https://asof.is/claim/clm_336AC8B041A1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_336AC8B041A1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,456,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_336AC8B041A1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2021, filed 2021-05-05"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 72,785,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_3ACBA8D93D83, https://asof.is/claim/clm_3ACBA8D93D83, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_3ACBA8D93D83","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"72,785,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3ACBA8D93D83","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2021, filed 2021-05-05"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,109,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_57D24A3D8A74, https://asof.is/claim/clm_57D24A3D8A74, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_57D24A3D8A74","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,109,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_57D24A3D8A74","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-05"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 8,054,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_6CBAE76E6610, https://asof.is/claim/clm_6CBAE76E6610, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_6CBAE76E6610","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,054,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6CBAE76E6610","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2021, filed 2021-05-05"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 654,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_99642DE8DD5D, https://asof.is/claim/clm_99642DE8DD5D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_99642DE8DD5D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"654,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99642DE8DD5D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2021, filed 2021-05-05"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 33,562,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_9B3045B3D04C, https://asof.is/claim/clm_9B3045B3D04C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_9B3045B3D04C","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"33,562,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9B3045B3D04C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-05-05"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,793,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_9F497245599A, https://asof.is/claim/clm_9F497245599A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_9F497245599A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,793,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9F497245599A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-05"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,772,817,349 shares\", as of 2021-06-30 (until 2021-09-30). Claim clm_08F7D872BEBD, https://asof.is/claim/clm_08F7D872BEBD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm.","url":"https://asof.is/claim/clm_08F7D872BEBD","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,772,817,349 shares","status":"superseded","assertable":true,"id":"clm_08F7D872BEBD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 33,800,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_0E0ED6C2D2F1, https://asof.is/claim/clm_0E0ED6C2D2F1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm.","url":"https://asof.is/claim/clm_0E0ED6C2D2F1","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"33,800,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0E0ED6C2D2F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,392,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_23A44C31565F, https://asof.is/claim/clm_23A44C31565F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm.","url":"https://asof.is/claim/clm_23A44C31565F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,392,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_23A44C31565F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 654,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_258F725B9941, https://asof.is/claim/clm_258F725B9941, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm.","url":"https://asof.is/claim/clm_258F725B9941","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"654,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_258F725B9941","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 8,658,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_4D07CC32DA31, https://asof.is/claim/clm_4D07CC32DA31, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm.","url":"https://asof.is/claim/clm_4D07CC32DA31","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,658,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4D07CC32DA31","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,189,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_4D5842D1AFBC, https://asof.is/claim/clm_4D5842D1AFBC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm.","url":"https://asof.is/claim/clm_4D5842D1AFBC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,189,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4D5842D1AFBC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 10,223,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_6EAE7D00A853, https://asof.is/claim/clm_6EAE7D00A853, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm.","url":"https://asof.is/claim/clm_6EAE7D00A853","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,223,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6EAE7D00A853","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 73,269,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_915AC243756D, https://asof.is/claim/clm_915AC243756D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm.","url":"https://asof.is/claim/clm_915AC243756D","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"73,269,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_915AC243756D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,546,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_48E46D6ED9A6, https://asof.is/claim/clm_48E46D6ED9A6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm.","url":"https://asof.is/claim/clm_48E46D6ED9A6","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,546,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_48E46D6ED9A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 73,795,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_8BE27EF7D3B2, https://asof.is/claim/clm_8BE27EF7D3B2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm.","url":"https://asof.is/claim/clm_8BE27EF7D3B2","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"73,795,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8BE27EF7D3B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 9,302,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_B27DA681BF8C, https://asof.is/claim/clm_B27DA681BF8C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm.","url":"https://asof.is/claim/clm_B27DA681BF8C","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,302,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B27DA681BF8C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 10,928,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_D28ACE81B29C, https://asof.is/claim/clm_D28ACE81B29C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm.","url":"https://asof.is/claim/clm_D28ACE81B29C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,928,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D28ACE81B29C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 672,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_F2D32AEB2B4A, https://asof.is/claim/clm_F2D32AEB2B4A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm.","url":"https://asof.is/claim/clm_F2D32AEB2B4A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"672,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F2D32AEB2B4A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 34,422,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_F790E66651DD, https://asof.is/claim/clm_F790E66651DD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm.","url":"https://asof.is/claim/clm_F790E66651DD","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"34,422,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F790E66651DD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 2,100,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_F9C12EA9C926, https://asof.is/claim/clm_F9C12EA9C926, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm.","url":"https://asof.is/claim/clm_F9C12EA9C926","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,100,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F9C12EA9C926","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2022-01-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,768,286,969 shares\", as of 2021-09-30 (until 2022-01-31). Claim clm_FC36D396E40F, https://asof.is/claim/clm_FC36D396E40F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm.","url":"https://asof.is/claim/clm_FC36D396E40F","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,768,286,969 shares","status":"superseded","assertable":true,"id":"clm_FC36D396E40F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 9,799,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_26D15FF3B04A, https://asof.is/claim/clm_26D15FF3B04A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm.","url":"https://asof.is/claim/clm_26D15FF3B04A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,799,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_26D15FF3B04A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 75,196,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_4C989819EA90, https://asof.is/claim/clm_4C989819EA90, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm.","url":"https://asof.is/claim/clm_4C989819EA90","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"75,196,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4C989819EA90","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 8,425,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_92EA1FC35D1F, https://asof.is/claim/clm_92EA1FC35D1F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm.","url":"https://asof.is/claim/clm_92EA1FC35D1F","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"8,425,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_92EA1FC35D1F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 35,802,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_962B09128298, https://asof.is/claim/clm_962B09128298, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm.","url":"https://asof.is/claim/clm_962B09128298","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"35,802,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_962B09128298","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 7,071,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_D4753923237F, https://asof.is/claim/clm_D4753923237F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm.","url":"https://asof.is/claim/clm_D4753923237F","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"7,071,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D4753923237F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 43,075,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_DA5BB69D989B, https://asof.is/claim/clm_DA5BB69D989B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm.","url":"https://asof.is/claim/clm_DA5BB69D989B","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"43,075,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DA5BB69D989B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,742,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_F186D437CBF8, https://asof.is/claim/clm_F186D437CBF8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm.","url":"https://asof.is/claim/clm_F186D437CBF8","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,742,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F186D437CBF8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2021, filed 2022-02-18"}},{"date":"2022-01-31","until":"2022-03-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,763,482,267 shares\", as of 2022-01-31 (until 2022-03-31). Claim clm_324EB82497B2, https://asof.is/claim/clm_324EB82497B2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm.","url":"https://asof.is/claim/clm_324EB82497B2","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,763,482,267 shares","status":"superseded","assertable":true,"id":"clm_324EB82497B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2021, filed 2022-02-18"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,912,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_1C12DA1AFF90, https://asof.is/claim/clm_1C12DA1AFF90, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm.","url":"https://asof.is/claim/clm_1C12DA1AFF90","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,912,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1C12DA1AFF90","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-03"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,675,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_2441D3B433A5, https://asof.is/claim/clm_2441D3B433A5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm.","url":"https://asof.is/claim/clm_2441D3B433A5","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,675,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2441D3B433A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2022, filed 2022-05-03"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 697,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_24C066E1F3E1, https://asof.is/claim/clm_24C066E1F3E1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm.","url":"https://asof.is/claim/clm_24C066E1F3E1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"697,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_24C066E1F3E1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2022, filed 2022-05-03"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 35,399,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_44B2ADC81A66, https://asof.is/claim/clm_44B2ADC81A66, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm.","url":"https://asof.is/claim/clm_44B2ADC81A66","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"35,399,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_44B2ADC81A66","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-05-03"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 11,895,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_8A05921A46AB, https://asof.is/claim/clm_8A05921A46AB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm.","url":"https://asof.is/claim/clm_8A05921A46AB","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"11,895,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A05921A46AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2022, filed 2022-05-03"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 2,447,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_9A8A8D8C7B07, https://asof.is/claim/clm_9A8A8D8C7B07, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm.","url":"https://asof.is/claim/clm_9A8A8D8C7B07","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,447,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9A8A8D8C7B07","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-03"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 74,007,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_B767032D0C72, https://asof.is/claim/clm_B767032D0C72, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm.","url":"https://asof.is/claim/clm_B767032D0C72","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"74,007,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B767032D0C72","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2022, filed 2022-05-03"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,750,942,289 shares\", as of 2022-03-31 (until 2022-06-30). Claim clm_CA76322E4A79, https://asof.is/claim/clm_CA76322E4A79, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm.","url":"https://asof.is/claim/clm_CA76322E4A79","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,750,942,289 shares","status":"superseded","assertable":true,"id":"clm_CA76322E4A79","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2022, filed 2022-05-03"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 11,257,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_3FFAC71D1875, https://asof.is/claim/clm_3FFAC71D1875, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm.","url":"https://asof.is/claim/clm_3FFAC71D1875","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"11,257,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3FFAC71D1875","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2022, filed 2022-08-02"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 74,202,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_49EE0D525A68, https://asof.is/claim/clm_49EE0D525A68, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm.","url":"https://asof.is/claim/clm_49EE0D525A68","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"74,202,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_49EE0D525A68","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2022, filed 2022-08-02"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,376,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_6DD49D4EE601, https://asof.is/claim/clm_6DD49D4EE601, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm.","url":"https://asof.is/claim/clm_6DD49D4EE601","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,376,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6DD49D4EE601","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-02"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 2,018,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_B88C88ADFFAE, https://asof.is/claim/clm_B88C88ADFFAE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm.","url":"https://asof.is/claim/clm_B88C88ADFFAE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,018,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B88C88ADFFAE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-02"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 8,937,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_B9EFB00ADC3F, https://asof.is/claim/clm_B9EFB00ADC3F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm.","url":"https://asof.is/claim/clm_B9EFB00ADC3F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,937,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9EFB00ADC3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2022, filed 2022-08-02"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 684,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_D0D6418B59F7, https://asof.is/claim/clm_D0D6418B59F7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm.","url":"https://asof.is/claim/clm_D0D6418B59F7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"684,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D0D6418B59F7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2022, filed 2022-08-02"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 36,490,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_D99C678FB2C8, https://asof.is/claim/clm_D99C678FB2C8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm.","url":"https://asof.is/claim/clm_D99C678FB2C8","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"36,490,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D99C678FB2C8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2022, filed 2022-08-02"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,751,219,743 shares\", as of 2022-06-30 (until 2022-09-30). Claim clm_DFFA512578F3, https://asof.is/claim/clm_DFFA512578F3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm.","url":"https://asof.is/claim/clm_DFFA512578F3","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,751,219,743 shares","status":"superseded","assertable":true,"id":"clm_DFFA512578F3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2022, filed 2022-08-02"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 10,410,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_1EE7A5C106ED, https://asof.is/claim/clm_1EE7A5C106ED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm.","url":"https://asof.is/claim/clm_1EE7A5C106ED","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,410,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1EE7A5C106ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 35,675,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_2C9B44DDBA52, https://asof.is/claim/clm_2C9B44DDBA52, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm.","url":"https://asof.is/claim/clm_2C9B44DDBA52","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"35,675,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2C9B44DDBA52","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 72,801,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_491BC57BD504, https://asof.is/claim/clm_491BC57BD504, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm.","url":"https://asof.is/claim/clm_491BC57BD504","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"72,801,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_491BC57BD504","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 9,594,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_521772051B63, https://asof.is/claim/clm_521772051B63, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm.","url":"https://asof.is/claim/clm_521772051B63","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,594,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_521772051B63","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,435,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_55CCFB617DE7, https://asof.is/claim/clm_55CCFB617DE7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm.","url":"https://asof.is/claim/clm_55CCFB617DE7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,435,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_55CCFB617DE7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 782,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_6768B441C8E0, https://asof.is/claim/clm_6768B441C8E0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm.","url":"https://asof.is/claim/clm_6768B441C8E0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"782,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6768B441C8E0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,770,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_886971CE1D04, https://asof.is/claim/clm_886971CE1D04, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm.","url":"https://asof.is/claim/clm_886971CE1D04","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,770,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_886971CE1D04","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2023-01-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,743,573,777 shares\", as of 2022-09-30 (until 2023-01-31). Claim clm_A47E0BC1EDCE, https://asof.is/claim/clm_A47E0BC1EDCE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm.","url":"https://asof.is/claim/clm_A47E0BC1EDCE","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,743,573,777 shares","status":"superseded","assertable":true,"id":"clm_A47E0BC1EDCE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 6,933,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_11981DF05BC7, https://asof.is/claim/clm_11981DF05BC7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm.","url":"https://asof.is/claim/clm_11981DF05BC7","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"6,933,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11981DF05BC7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,888,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_2B9EF111FA51, https://asof.is/claim/clm_2B9EF111FA51, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm.","url":"https://asof.is/claim/clm_2B9EF111FA51","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,888,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B9EF111FA51","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 8,362,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_504246A9C0D6, https://asof.is/claim/clm_504246A9C0D6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm.","url":"https://asof.is/claim/clm_504246A9C0D6","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"8,362,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_504246A9C0D6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 43,653,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_6FD3450A3DD5, https://asof.is/claim/clm_6FD3450A3DD5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm.","url":"https://asof.is/claim/clm_6FD3450A3DD5","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"43,653,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6FD3450A3DD5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 74,438,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_A18A3F048BE2, https://asof.is/claim/clm_A18A3F048BE2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm.","url":"https://asof.is/claim/clm_A18A3F048BE2","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"74,438,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A18A3F048BE2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 36,686,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_B43602CFF805, https://asof.is/claim/clm_B43602CFF805, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm.","url":"https://asof.is/claim/clm_B43602CFF805","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"36,686,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B43602CFF805","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 9,882,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_B5EA4556B88D, https://asof.is/claim/clm_B5EA4556B88D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm.","url":"https://asof.is/claim/clm_B5EA4556B88D","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,882,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B5EA4556B88D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-17"}},{"date":"2023-01-31","until":"2023-03-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,737,946,233 shares\", as of 2023-01-31 (until 2023-03-31). Claim clm_415D9C1703CA, https://asof.is/claim/clm_415D9C1703CA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm.","url":"https://asof.is/claim/clm_415D9C1703CA","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,737,946,233 shares","status":"superseded","assertable":true,"id":"clm_415D9C1703CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2022, filed 2023-02-17"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,318,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_021A4A96F575, https://asof.is/claim/clm_021A4A96F575, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm.","url":"https://asof.is/claim/clm_021A4A96F575","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,318,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_021A4A96F575","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 9,161,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_14B748327E60, https://asof.is/claim/clm_14B748327E60, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm.","url":"https://asof.is/claim/clm_14B748327E60","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,161,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_14B748327E60","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 73,794,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_29B334F286FF, https://asof.is/claim/clm_29B334F286FF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm.","url":"https://asof.is/claim/clm_29B334F286FF","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"73,794,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_29B334F286FF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,509,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_4B304DFC779C, https://asof.is/claim/clm_4B304DFC779C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm.","url":"https://asof.is/claim/clm_4B304DFC779C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,509,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4B304DFC779C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,738,946,799 shares\", as of 2023-03-31 (until 2023-06-30). Claim clm_570FAE00E73C, https://asof.is/claim/clm_570FAE00E73C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm.","url":"https://asof.is/claim/clm_570FAE00E73C","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,738,946,799 shares","status":"superseded","assertable":true,"id":"clm_570FAE00E73C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 654,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_602C8D08E319, https://asof.is/claim/clm_602C8D08E319, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm.","url":"https://asof.is/claim/clm_602C8D08E319","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"654,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_602C8D08E319","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 37,010,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_BCA71643FBC3, https://asof.is/claim/clm_BCA71643FBC3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm.","url":"https://asof.is/claim/clm_BCA71643FBC3","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"37,010,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BCA71643FBC3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,747,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_BDD05EB44D8B, https://asof.is/claim/clm_BDD05EB44D8B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm.","url":"https://asof.is/claim/clm_BDD05EB44D8B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,747,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BDD05EB44D8B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2023, filed 2023-05-04"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,735,357,980 shares\", as of 2023-06-30 (until 2023-09-30). Claim clm_027756C1CA20, https://asof.is/claim/clm_027756C1CA20, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm.","url":"https://asof.is/claim/clm_027756C1CA20","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,735,357,980 shares","status":"superseded","assertable":true,"id":"clm_027756C1CA20","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,542,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_2E82AF12DD3E, https://asof.is/claim/clm_2E82AF12DD3E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm.","url":"https://asof.is/claim/clm_2E82AF12DD3E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,542,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2E82AF12DD3E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 37,174,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_2FAA1610921D, https://asof.is/claim/clm_2FAA1610921D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm.","url":"https://asof.is/claim/clm_2FAA1610921D","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"37,174,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2FAA1610921D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,835,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_34B14167D6F5, https://asof.is/claim/clm_34B14167D6F5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm.","url":"https://asof.is/claim/clm_34B14167D6F5","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,835,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_34B14167D6F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,375,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_53901BDE4225, https://asof.is/claim/clm_53901BDE4225, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm.","url":"https://asof.is/claim/clm_53901BDE4225","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,375,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_53901BDE4225","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 73,354,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_58DF422102D3, https://asof.is/claim/clm_58DF422102D3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm.","url":"https://asof.is/claim/clm_58DF422102D3","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"73,354,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_58DF422102D3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,978,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_6B2DDDB45AF4, https://asof.is/claim/clm_6B2DDDB45AF4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm.","url":"https://asof.is/claim/clm_6B2DDDB45AF4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,978,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6B2DDDB45AF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 715,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_9ED86C910D2E, https://asof.is/claim/clm_9ED86C910D2E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm.","url":"https://asof.is/claim/clm_9ED86C910D2E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"715,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9ED86C910D2E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2023, filed 2023-08-03"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,709,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_01C8A8BA9FB2, https://asof.is/claim/clm_01C8A8BA9FB2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm.","url":"https://asof.is/claim/clm_01C8A8BA9FB2","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,709,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_01C8A8BA9FB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2023, filed 2023-11-01"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 10,143,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_3885AF18E04D, https://asof.is/claim/clm_3885AF18E04D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm.","url":"https://asof.is/claim/clm_3885AF18E04D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,143,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3885AF18E04D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2023, filed 2023-11-01"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 37,481,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_44CDC24CAD4E, https://asof.is/claim/clm_44CDC24CAD4E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm.","url":"https://asof.is/claim/clm_44CDC24CAD4E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"37,481,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_44CDC24CAD4E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2023, filed 2023-11-01"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,436,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_47F26EE33149, https://asof.is/claim/clm_47F26EE33149, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm.","url":"https://asof.is/claim/clm_47F26EE33149","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,436,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_47F26EE33149","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-01"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 72,090,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_7F56B9F9D8D3, https://asof.is/claim/clm_7F56B9F9D8D3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm.","url":"https://asof.is/claim/clm_7F56B9F9D8D3","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"72,090,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7F56B9F9D8D3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2023, filed 2023-11-01"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,647,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_B41FB990A838, https://asof.is/claim/clm_B41FB990A838, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm.","url":"https://asof.is/claim/clm_B41FB990A838","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,647,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B41FB990A838","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-01"}},{"date":"2023-09-30","until":"2024-01-31","published":"2023-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,736,058,536 shares\", as of 2023-09-30 (until 2024-01-31). Claim clm_DDC41F7C4050, https://asof.is/claim/clm_DDC41F7C4050, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm.","url":"https://asof.is/claim/clm_DDC41F7C4050","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,736,058,536 shares","status":"superseded","assertable":true,"id":"clm_DDC41F7C4050","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2023, filed 2023-11-01"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 672,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_F557BBEDA577, https://asof.is/claim/clm_F557BBEDA577, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm.","url":"https://asof.is/claim/clm_F557BBEDA577","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"672,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F557BBEDA577","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2023, filed 2023-11-01"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 5,723,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_1E79DAD01E1C, https://asof.is/claim/clm_1E79DAD01E1C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm.","url":"https://asof.is/claim/clm_1E79DAD01E1C","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"5,723,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E79DAD01E1C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2023, filed 2024-02-16"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 6,478,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_492DDC48ED34, https://asof.is/claim/clm_492DDC48ED34, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm.","url":"https://asof.is/claim/clm_492DDC48ED34","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"6,478,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_492DDC48ED34","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2023, filed 2024-02-16"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 38,603,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_5BE6B18DE8F9, https://asof.is/claim/clm_5BE6B18DE8F9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm.","url":"https://asof.is/claim/clm_5BE6B18DE8F9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"38,603,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5BE6B18DE8F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2023, filed 2024-02-16"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 73,214,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_603966F4450A, https://asof.is/claim/clm_603966F4450A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm.","url":"https://asof.is/claim/clm_603966F4450A","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"73,214,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_603966F4450A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2023, filed 2024-02-16"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,741,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_616A4BA20B30, https://asof.is/claim/clm_616A4BA20B30, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm.","url":"https://asof.is/claim/clm_616A4BA20B30","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,741,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_616A4BA20B30","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2023, filed 2024-02-16"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,896,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_658B87946AB9, https://asof.is/claim/clm_658B87946AB9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm.","url":"https://asof.is/claim/clm_658B87946AB9","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,896,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_658B87946AB9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2023, filed 2024-02-16"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 40,109,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_8BADD4D79F8F, https://asof.is/claim/clm_8BADD4D79F8F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm.","url":"https://asof.is/claim/clm_8BADD4D79F8F","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"40,109,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8BADD4D79F8F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2023, filed 2024-02-16"}},{"date":"2024-01-31","until":"2024-03-31","published":"2024-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,735,184,289 shares\", as of 2024-01-31 (until 2024-03-31). Claim clm_BBA1010F4237, https://asof.is/claim/clm_BBA1010F4237, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm.","url":"https://asof.is/claim/clm_BBA1010F4237","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,735,184,289 shares","status":"superseded","assertable":true,"id":"clm_BBA1010F4237","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2023, filed 2024-02-16"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 9,964,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_60D18C4ED290, https://asof.is/claim/clm_60D18C4ED290, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm.","url":"https://asof.is/claim/clm_60D18C4ED290","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"9,964,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_60D18C4ED290","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 684,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_67490CE86700, https://asof.is/claim/clm_67490CE86700, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm.","url":"https://asof.is/claim/clm_67490CE86700","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"684,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_67490CE86700","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,739,633,759 shares\", as of 2024-03-31 (until 2024-06-30). Claim clm_97F2C8360ADC, https://asof.is/claim/clm_97F2C8360ADC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm.","url":"https://asof.is/claim/clm_97F2C8360ADC","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,739,633,759 shares","status":"superseded","assertable":true,"id":"clm_97F2C8360ADC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 72,467,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_A3E39CBB1AE7, https://asof.is/claim/clm_A3E39CBB1AE7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm.","url":"https://asof.is/claim/clm_A3E39CBB1AE7","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"72,467,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A3E39CBB1AE7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,225,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_B072725BD09E, https://asof.is/claim/clm_B072725BD09E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm.","url":"https://asof.is/claim/clm_B072725BD09E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,225,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B072725BD09E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,284,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_BE85A98DAC5B, https://asof.is/claim/clm_BE85A98DAC5B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm.","url":"https://asof.is/claim/clm_BE85A98DAC5B","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,284,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BE85A98DAC5B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 38,810,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_C93071E72423, https://asof.is/claim/clm_C93071E72423, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm.","url":"https://asof.is/claim/clm_C93071E72423","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"38,810,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C93071E72423","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,386,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_FDE13F28F4C1, https://asof.is/claim/clm_FDE13F28F4C1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm.","url":"https://asof.is/claim/clm_FDE13F28F4C1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,386,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FDE13F28F4C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-02"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,987,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_16E584C7B895, https://asof.is/claim/clm_16E584C7B895, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm.","url":"https://asof.is/claim/clm_16E584C7B895","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,987,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_16E584C7B895","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2024, filed 2024-07-31"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,739,897,004 shares\", as of 2024-06-30 (until 2024-09-30). Claim clm_17BF8DBB11AD, https://asof.is/claim/clm_17BF8DBB11AD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm.","url":"https://asof.is/claim/clm_17BF8DBB11AD","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,739,897,004 shares","status":"superseded","assertable":true,"id":"clm_17BF8DBB11AD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2024, filed 2024-07-31"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 73,017,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_73D720E01EFC, https://asof.is/claim/clm_73D720E01EFC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm.","url":"https://asof.is/claim/clm_73D720E01EFC","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"73,017,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_73D720E01EFC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-07-31"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 39,318,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_963EBDDEF424, https://asof.is/claim/clm_963EBDDEF424, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm.","url":"https://asof.is/claim/clm_963EBDDEF424","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"39,318,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_963EBDDEF424","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2024, filed 2024-07-31"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,302,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_B3E333AEC169, https://asof.is/claim/clm_B3E333AEC169, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm.","url":"https://asof.is/claim/clm_B3E333AEC169","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,302,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B3E333AEC169","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2024, filed 2024-07-31"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 698,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_B51405589AC1, https://asof.is/claim/clm_B51405589AC1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm.","url":"https://asof.is/claim/clm_B51405589AC1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"698,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B51405589AC1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2024, filed 2024-07-31"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 10,377,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_BC21405CF5E5, https://asof.is/claim/clm_BC21405CF5E5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm.","url":"https://asof.is/claim/clm_BC21405CF5E5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,377,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC21405CF5E5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2024, filed 2024-07-31"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,669,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_D714148AE67A, https://asof.is/claim/clm_D714148AE67A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm.","url":"https://asof.is/claim/clm_D714148AE67A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,669,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D714148AE67A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2024, filed 2024-07-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 10,635,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_12D7EF8B99CE, https://asof.is/claim/clm_12D7EF8B99CE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm.","url":"https://asof.is/claim/clm_12D7EF8B99CE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,635,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_12D7EF8B99CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,558,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_1FFA2B3FBAF9, https://asof.is/claim/clm_1FFA2B3FBAF9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm.","url":"https://asof.is/claim/clm_1FFA2B3FBAF9","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,558,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1FFA2B3FBAF9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,859,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_23C6088E7F70, https://asof.is/claim/clm_23C6088E7F70, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm.","url":"https://asof.is/claim/clm_23C6088E7F70","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,859,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_23C6088E7F70","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 713,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_4031E5A84FE8, https://asof.is/claim/clm_4031E5A84FE8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm.","url":"https://asof.is/claim/clm_4031E5A84FE8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"713,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4031E5A84FE8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,646,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_489645837B5D, https://asof.is/claim/clm_489645837B5D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm.","url":"https://asof.is/claim/clm_489645837B5D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,646,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_489645837B5D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-01-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,734,455,213 shares\", as of 2024-09-30 (until 2025-01-31). Claim clm_B9E574E3CE32, https://asof.is/claim/clm_B9E574E3CE32, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm.","url":"https://asof.is/claim/clm_B9E574E3CE32","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,734,455,213 shares","status":"superseded","assertable":true,"id":"clm_B9E574E3CE32","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 74,356,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_BCEDE84B5D8A, https://asof.is/claim/clm_BCEDE84B5D8A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm.","url":"https://asof.is/claim/clm_BCEDE84B5D8A","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"74,356,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BCEDE84B5D8A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 39,796,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_CE6B68D9DE0E, https://asof.is/claim/clm_CE6B68D9DE0E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm.","url":"https://asof.is/claim/clm_CE6B68D9DE0E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"39,796,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CE6B68D9DE0E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 81,414,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_114AF086ADE9, https://asof.is/claim/clm_114AF086ADE9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_114AF086ADE9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"81,414,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_114AF086ADE9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2024, filed 2025-02-21"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 47,664,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_117E87574745, https://asof.is/claim/clm_117E87574745, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_117E87574745","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"47,664,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_117E87574745","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2024, filed 2025-02-21"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 6,825,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_6578DDE458E0, https://asof.is/claim/clm_6578DDE458E0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_6578DDE458E0","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"6,825,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6578DDE458E0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-21"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 41,950,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_AC0EC8434FB1, https://asof.is/claim/clm_AC0EC8434FB1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_AC0EC8434FB1","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"41,950,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AC0EC8434FB1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-21"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,844,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_AD76C5C835C9, https://asof.is/claim/clm_AD76C5C835C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_AD76C5C835C9","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,844,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AD76C5C835C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2024, filed 2025-02-21"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,616,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_BE323442D575, https://asof.is/claim/clm_BE323442D575, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_BE323442D575","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,616,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BE323442D575","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2024, filed 2025-02-21"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 13,402,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_CF3E98D0B268, https://asof.is/claim/clm_CF3E98D0B268, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_CF3E98D0B268","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"13,402,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF3E98D0B268","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-21"}},{"date":"2025-01-31","until":"2025-03-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,734,323,411 shares\", as of 2025-01-31 (until 2025-03-31). Claim clm_C9A2257584AB, https://asof.is/claim/clm_C9A2257584AB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_C9A2257584AB","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,734,323,411 shares","status":"superseded","assertable":true,"id":"clm_C9A2257584AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2024, filed 2025-02-21"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,325,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_1188A2534E22, https://asof.is/claim/clm_1188A2534E22, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm.","url":"https://asof.is/claim/clm_1188A2534E22","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,325,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1188A2534E22","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2025, filed 2025-04-30"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 48,811,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_263DBDF600A7, https://asof.is/claim/clm_263DBDF600A7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm.","url":"https://asof.is/claim/clm_263DBDF600A7","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"48,811,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_263DBDF600A7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2025, filed 2025-04-30"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 81,448,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_27D6994F8B52, https://asof.is/claim/clm_27D6994F8B52, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm.","url":"https://asof.is/claim/clm_27D6994F8B52","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"81,448,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_27D6994F8B52","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2025, filed 2025-04-30"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 716,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_5AF0089A1631, https://asof.is/claim/clm_5AF0089A1631, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm.","url":"https://asof.is/claim/clm_5AF0089A1631","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"716,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5AF0089A1631","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2025, filed 2025-04-30"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,693,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_75BE91C87765, https://asof.is/claim/clm_75BE91C87765, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm.","url":"https://asof.is/claim/clm_75BE91C87765","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,693,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_75BE91C87765","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2025, filed 2025-04-30"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,532,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_7C1DF4950D60, https://asof.is/claim/clm_7C1DF4950D60, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm.","url":"https://asof.is/claim/clm_7C1DF4950D60","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,532,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7C1DF4950D60","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2025, filed 2025-04-30"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 10,358,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_B19E42064034, https://asof.is/claim/clm_B19E42064034, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm.","url":"https://asof.is/claim/clm_B19E42064034","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,358,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B19E42064034","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2025, filed 2025-04-30"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,739,836,465 shares\", as of 2025-03-31 (until 2025-06-30). Claim clm_D943BAA75A0F, https://asof.is/claim/clm_D943BAA75A0F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm.","url":"https://asof.is/claim/clm_D943BAA75A0F","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,739,836,465 shares","status":"superseded","assertable":true,"id":"clm_D943BAA75A0F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2025, filed 2025-04-30"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 50,565,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_11FDBB86160D, https://asof.is/claim/clm_11FDBB86160D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm.","url":"https://asof.is/claim/clm_11FDBB86160D","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"50,565,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11FDBB86160D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2025, filed 2025-07-30"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 83,999,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_217C000CA5A2, https://asof.is/claim/clm_217C000CA5A2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm.","url":"https://asof.is/claim/clm_217C000CA5A2","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"83,999,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_217C000CA5A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2025, filed 2025-07-30"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 725,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_B9E52815E3A9, https://asof.is/claim/clm_B9E52815E3A9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm.","url":"https://asof.is/claim/clm_B9E52815E3A9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"725,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9E52815E3A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2025, filed 2025-07-30"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,052,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_D4D65248DFB6, https://asof.is/claim/clm_D4D65248DFB6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm.","url":"https://asof.is/claim/clm_D4D65248DFB6","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,052,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D4D65248DFB6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2025, filed 2025-07-30"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,779,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_E37C754C8FCC, https://asof.is/claim/clm_E37C754C8FCC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm.","url":"https://asof.is/claim/clm_E37C754C8FCC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,779,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E37C754C8FCC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2025, filed 2025-07-30"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 11,142,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_E9EFA461ED0C, https://asof.is/claim/clm_E9EFA461ED0C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm.","url":"https://asof.is/claim/clm_E9EFA461ED0C","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"11,142,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E9EFA461ED0C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2025, filed 2025-07-30"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,951,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_F462DB1216CF, https://asof.is/claim/clm_F462DB1216CF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm.","url":"https://asof.is/claim/clm_F462DB1216CF","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,951,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F462DB1216CF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2025, filed 2025-07-30"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,740,459,014 shares\", as of 2025-06-30 (until 2025-09-30). Claim clm_F9BD3860CF3E, https://asof.is/claim/clm_F9BD3860CF3E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm.","url":"https://asof.is/claim/clm_F9BD3860CF3E","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,740,459,014 shares","status":"superseded","assertable":true,"id":"clm_F9BD3860CF3E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2025, filed 2025-07-30"}},{"date":"2025-09-30","until":"2026-01-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,738,871,947 shares\", as of 2025-09-30 (until 2026-01-31). Claim clm_0F8EC0C78816, https://asof.is/claim/clm_0F8EC0C78816, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_0F8EC0C78816","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,738,871,947 shares","status":"superseded","assertable":true,"id":"clm_0F8EC0C78816","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-10-29"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 766,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_1266BBB313EF, https://asof.is/claim/clm_1266BBB313EF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_1266BBB313EF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"766,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1266BBB313EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2025, filed 2025-10-29"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,644,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_2BCC0DA601EA, https://asof.is/claim/clm_2BCC0DA601EA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_2BCC0DA601EA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,644,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2BCC0DA601EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-29"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 11,369,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_4D4D4E6FC869, https://asof.is/claim/clm_4D4D4E6FC869, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_4D4D4E6FC869","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"11,369,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4D4D4E6FC869","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-10-29"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,511,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_4D88D9F7190C, https://asof.is/claim/clm_4D88D9F7190C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_4D88D9F7190C","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,511,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4D88D9F7190C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-29"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 84,181,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_87D9C9A99CA7, https://asof.is/claim/clm_87D9C9A99CA7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_87D9C9A99CA7","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"84,181,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_87D9C9A99CA7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-29"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,057,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_94C2592AE159, https://asof.is/claim/clm_94C2592AE159, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_94C2592AE159","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,057,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94C2592AE159","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-29"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 50,954,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_D5EE83B1870A, https://asof.is/claim/clm_D5EE83B1870A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_D5EE83B1870A","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"50,954,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D5EE83B1870A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-29"}},{"date":"2025-12-31","until":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,942,000,000 United States dollar\", as of 2025-12-31. Claim clm_0537D98543E9, https://asof.is/claim/clm_0537D98543E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_0537D98543E9","accessed":"2026-11-09"},"kind":"money","predicate":"research_and_development","value":"2,942,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_0537D98543E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 52,130,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_233C6F73AC72, https://asof.is/claim/clm_233C6F73AC72, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_233C6F73AC72","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"52,130,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_233C6F73AC72","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 8,053,000,000 United States dollar\", as of 2025-12-31. Claim clm_551396362E4C, https://asof.is/claim/clm_551396362E4C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_551396362E4C","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"8,053,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_551396362E4C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 86,713,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_61EE170DDFF9, https://asof.is/claim/clm_61EE170DDFF9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_61EE170DDFF9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"86,713,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_61EE170DDFF9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 6,524,000,000 United States dollar\", as of 2025-12-31. Claim clm_76AC317902A6, https://asof.is/claim/clm_76AC317902A6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_76AC317902A6","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"6,524,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_76AC317902A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 44,328,000,000 United States dollar\", as of 2025-12-31. Claim clm_7C1D7352CFA6, https://asof.is/claim/clm_7C1D7352CFA6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_7C1D7352CFA6","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"44,328,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_7C1D7352CFA6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 8,522,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_C0C2E64C6F88, https://asof.is/claim/clm_C0C2E64C6F88, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_C0C2E64C6F88","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,522,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C0C2E64C6F88","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2025, filed 2026-02-20"}},{"date":"2026-01-31","until":"2026-03-31","published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,737,682,887 shares\", as of 2026-01-31 (until 2026-03-31). Claim clm_98DC25486509, https://asof.is/claim/clm_98DC25486509, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_98DC25486509","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,737,682,887 shares","status":"superseded","assertable":true,"id":"clm_98DC25486509","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2025, filed 2026-02-20"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,077,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_0713CDEDD078, https://asof.is/claim/clm_0713CDEDD078, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm.","url":"https://asof.is/claim/clm_0713CDEDD078","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,077,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0713CDEDD078","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,741,812,429 shares\", as of 2026-03-31 (until 2026-06-30). Claim clm_0EA7146A2063, https://asof.is/claim/clm_0EA7146A2063, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm.","url":"https://asof.is/claim/clm_0EA7146A2063","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,741,812,429 shares","status":"superseded","assertable":true,"id":"clm_0EA7146A2063","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,345,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_1C0A2724D779, https://asof.is/claim/clm_1C0A2724D779, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm.","url":"https://asof.is/claim/clm_1C0A2724D779","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,345,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1C0A2724D779","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 110,429,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_1E6184001C61, https://asof.is/claim/clm_1E6184001C61, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm.","url":"https://asof.is/claim/clm_1E6184001C61","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"110,429,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E6184001C61","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 52,061,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_3A1641DA4DD9, https://asof.is/claim/clm_3A1641DA4DD9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm.","url":"https://asof.is/claim/clm_3A1641DA4DD9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"52,061,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3A1641DA4DD9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 11,164,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_EF0BC6C103EE, https://asof.is/claim/clm_EF0BC6C103EE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm.","url":"https://asof.is/claim/clm_EF0BC6C103EE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"11,164,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EF0BC6C103EE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 767,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_F408F42211E9, https://asof.is/claim/clm_F408F42211E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm.","url":"https://asof.is/claim/clm_F408F42211E9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"767,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F408F42211E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 6,803,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_F4A9C9EE7593, https://asof.is/claim/clm_F4A9C9EE7593, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm.","url":"https://asof.is/claim/clm_F4A9C9EE7593","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,803,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F4A9C9EE7593","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2026, filed 2026-04-29"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 928,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_260A61887540, https://asof.is/claim/clm_260A61887540, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm.","url":"https://asof.is/claim/clm_260A61887540","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"928,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_260A61887540","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2026, filed 2026-07-28"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,693,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_2A39068943F3, https://asof.is/claim/clm_2A39068943F3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm.","url":"https://asof.is/claim/clm_2A39068943F3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,693,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2A39068943F3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2026, filed 2026-07-28"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 5,104,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_427132599EAB, https://asof.is/claim/clm_427132599EAB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm.","url":"https://asof.is/claim/clm_427132599EAB","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,104,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_427132599EAB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2026, filed 2026-07-28"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 51,110,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_6E93433192ED, https://asof.is/claim/clm_6E93433192ED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm.","url":"https://asof.is/claim/clm_6E93433192ED","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"51,110,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E93433192ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2026, filed 2026-07-28"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 12,593,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_88335AA7BB99, https://asof.is/claim/clm_88335AA7BB99, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm.","url":"https://asof.is/claim/clm_88335AA7BB99","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"12,593,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_88335AA7BB99","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2026, filed 2026-07-28"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 109,215,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_9F11A9C39281, https://asof.is/claim/clm_9F11A9C39281, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm.","url":"https://asof.is/claim/clm_9F11A9C39281","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"109,215,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9F11A9C39281","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2026, filed 2026-07-28"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 892,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_A04DCE763037, https://asof.is/claim/clm_A04DCE763037, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm.","url":"https://asof.is/claim/clm_A04DCE763037","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"892,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A04DCE763037","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2026, filed 2026-07-28"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,730,383,296 shares\", as of 2026-06-30 (until 2026-09-30). Claim clm_AC459049B414, https://asof.is/claim/clm_AC459049B414, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm.","url":"https://asof.is/claim/clm_AC459049B414","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,730,383,296 shares","status":"superseded","assertable":true,"id":"clm_AC459049B414","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2026, filed 2026-07-28"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 13,013,000,000 United States dollar\", as of 2026-09-30. Claim clm_080974839279, https://asof.is/claim/clm_080974839279, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_080974839279","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"13,013,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_080974839279","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 920,000,000 United States dollar\", as of 2026-09-30. Claim clm_0E055280C61A, https://asof.is/claim/clm_0E055280C61A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_0E055280C61A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"920,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_0E055280C61A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 51,027,000,000 United States dollar\", as of 2026-09-30. Claim clm_1774BA675DC1, https://asof.is/claim/clm_1774BA675DC1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_1774BA675DC1","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"51,027,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_1774BA675DC1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 920,000,000 United States dollar\", as of 2026-09-30. Claim clm_1E22065402A1, https://asof.is/claim/clm_1E22065402A1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_1E22065402A1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_research_and_development","value":"920,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_1E22065402A1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,358,000,000 United States dollar\", as of 2026-09-30. Claim clm_2416CD508AED, https://asof.is/claim/clm_2416CD508AED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_2416CD508AED","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,358,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_2416CD508AED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 108,247,000,000 United States dollar\", as of 2026-09-30. Claim clm_408FF4DCACA7, https://asof.is/claim/clm_408FF4DCACA7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_408FF4DCACA7","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"108,247,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_408FF4DCACA7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,731,941,601 shares\", as of 2026-09-30. Claim clm_7B940234185D, https://asof.is/claim/clm_7B940234185D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_7B940234185D","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,731,941,601 shares","status":"valid","assertable":true,"id":"clm_7B940234185D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,052,000,000 United States dollar\", as of 2026-09-30. Claim clm_D623F1D8651F, https://asof.is/claim/clm_D623F1D8651F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_D623F1D8651F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,052,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_D623F1D8651F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-04"}}],"complete":true,"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)","sec-filing":"parsed from the SEC filing"}}}